EP0693937A1

EP0693937A1 - Hiv-1 vaccines, antibody compositions related thereto, and therapeutic and prophylactic uses thereof

Info

Publication number: EP0693937A1
Application number: EP94912874A
Authority: EP
Inventors: Karl W. Hasel; Paul J. Maddon
Original assignee: Progenics Pharmaceuticals Inc
Current assignee: Progenics Pharmaceuticals Inc
Priority date: 1993-03-26
Filing date: 1994-03-25
Publication date: 1996-01-31
Anticipated expiration: 2014-03-25
Also published as: AU672693B2; AU6525194A; US5869624A; EP0693937A4; ATE228852T1; DE69431835D1; WO1994022477A1; DE69431835T2; EP0693937B1; CA2158171A1; US5886163A

Abstract

The invention provides a recombinant nucleic acid molecule which encodes a mutant HIV-1 gp120 envelope glycoprotein, vaccines comprising the mutant HIV-1 envelope glycoprotein, antibodies and methods of treating individuals.

Description

HIV-l VACCINES. ANTIBODY COMPOSITIONS RELATED THERETO. AND THERAPEUTIC AND PROPHYLACTIC USES THEREOF

Background of the Invention

Throughout this application, various publications are referenced by Arabic numerals. Full citations for these references may be found at the end of the specification immediately preceding the claims. The disclosure of these publications is hereby incorporated by reference into this application to describe more fully the art to which this invention pertains.

The life cycle of animal viruses is characterized by a series of events that are required for the productive infection of the host cell. The initial step in the replicative cycle is the attachment of the virus to the cell surface, which attachment is mediated by the specific interaction of the viral attachment protein (VAP) to receptors on the surface of the target cell. The differential pattern of expression of these receptors is largely responsible for the host range and tropic properties of viruses. In addition, an effective immune response against many viruses is mediated through neutralizing antibodies directed against the VAP. The interaction of the VAP with cellular receptors and the immune system therefore plays a critical role in infection and pathogenesis of viral disease.

The human immunodeficiency virus type 1 (HIV-l) infects primarily helper T lymphocytes, dendritic cells, and monocytes/macrophages--cells that express surface CD4-- leading to a gradual loss of immune function. This loss of function results in the development of the human acquired immunodeficiency syndrome (AIDS) (l) . The initial phase of the HIV-l replicative cycle involves the high-affinity interaction between the HIV-l exterior envelope glycoprotein gpl20 and cell surface CD4 (K_d approximately 4 x 10^"9 M) (2) . Several lines of evidence demonstrate the requirement of this interaction for viral infectivity. The introduction into CD4" human cells of cDNA encoding CD4 is sufficient to render otherwise resistant cells susceptible to HIV-l infection (3) . In vivo, viral infection appears to be restricted to cells expressing CD4, indicating that the cellular tropism of HIV-l is largely determined by the pattern of cellular expression of CD4. Following the binding of HIV-l gpl20 to cell surface CD4, viral and target cell membranes fuse by a mechanism that is poorly understood, resulting in the introduction of the viral capsid into the target cell cytoplasm (4) .

Mature CD4 has a relative molecular mass (Mr) of 55 kDa and consists of an N-terminal 372-amino acid extracellular domain containing four tandem immunoglobulin-like regions (V1-V4) , followed by a 23-amino acid transmembrane domain and a 38-amino acid cytoplasmic segment (5, 6) . In experiments using truncated sCD4 proteins, it has been shown that the determinants for high-affinity binding to HIV-l gpl20 lie solely within the N-terminal immunoglobulin-like domain (VI) (7-9) . Mutational analysis of VI has defined a discrete binding site (residues 38-52) that comprises a region structurally homologous to the second complementarity-determining region (CDR2) of immunoglobulin genes (9) .

The production of large quantities of sCD4 has permitted a structural analysis of the two N-terminal immunoglobulin- like domains (V1V2) . The structure determined at 2.3 angstrom resolution reveals that the molecule has two tightly-associated domains, each of which contains the immunoglobulin-fold connected by a continuous beta strand. The putative binding sites for monoclonal antibodies, class II major histocompatibility complex (MHC) molecules, and HIV-l gpl20, as determined by mutational analyses, map on the molecular surface (10, 11) .

The HIV-l envelope gene env encodes an envelope glycoprotein precursor, gpl60, which is cleaved by cellular proteases before transport to the plasma membrane to yield gpl20 and gp41. The membrane-spanning glycoprotein, gp41, is non- covalently associated with gpl20, a purely extracellular glycoprotein. The mature gpl20 molecule is heavily glycosylated (approximately 24 N-linked oligosaccharides) , contains approximately 480 amino acid residues with 9 intra- chain disulfide bonds (12) , and projects from the viral membrane as a dimeric or multimeric molecule (13) .

Mutational studies of HIV-l gpl20 have delineated important functional regions of the molecule. The regions of gpl20 that interact with gp41 map primarily to the N- and C- termini (14) . The predominant strain-specific neutralizing epitope on gpl20 is located in the 32-34 amino acid residue third variable loop, herein referred to as the V3 loop, which resides near the center of the gpl20 sequence (15) . The CD4 binding site maps to discontinuous regions of gpl20 that include highly conserved or invariant amino acid residues in the second, third, and fourth conserved domains (the C2, C3, and C4 domains) of gpl20 (16). It has been postulated that a small pocket formed by these conserved residues within gpl20 could accommodate the CDR2 loop of CD4, a region defined by mutational analyses as important in interacting with gpl20 (17) . HIV-l gpl20 not only mediates viral attachment to surface CD4 molecules, but also serves as the major target of antibodies which neutralize non-cell-associated virus and inhibit cell to cell viral transmission.

There are two major classifications of HIV-l-neutralizing antibodies: type-specific and group-common (15). Type- specific neutralizing antibodies primarily recognize linear determinants in the highly variable V3 loop of gpl20. These antibodies act by inhibiting fusion between HIV-l and the target cell membrane, and generally neutralize only a particular isolate of, or closely related strains of, HIV-l. Sequence variation within the V3 loop, as well as outside of this region, permits viruses to escape neutralization by anti-V3 loop antibodies. In contrast, group-common neutralizing antibodies primarily recognize discontinuous or conformational epitopes in gpl20, and possess the ability to neutralize a diverse range of HIV-l isolates. These broadly neutralizing antibodies often recognize a site on gpl20 which overlaps the highly conserved CD4-binding site, and thus inhibits gpl20-CD4 binding.

A structural relationship has been demonstrated between the V3 loop and the C4 region of gpl20 which region constitutes both part of the CD4 binding site and part of the conserved neutralization epitopes. It was observed that deleting the V3 loop resulted in significantly increased binding of a panel of broadly neutralizing hMoAbs (neutralizing human monoclonal antibodies) to the CD4 binding site (18) .

A major goal in AIDS vaccine development is to develop a vaccine able to protect a subject against the numerous genetic variants of HIV-l that infect humans. Although cell-mediated immune responses might serve to control infection in HIV-l-infected individuals, several lines of evidence demonstrate that protection against infection is mainly mediated by neutralizing antibodies directed against gpl20. Early experiments showed that immunization of chimpanzees with recombinant gpl20 induced a protective immune response against challenge with the homologous HIV-l strain (17) . This protection correlated with the presence of high-titer neutralizing antibodies against the V3 loop of gpl20. In addition, passive immunization of chimpanzees with a V3-loop neutralizing monoclonal antibody resulted in protection against challenge with the homologous HIV-l strain (19) . Although protection against challenge was demonstrated in these two experiments, recent studies have questioned the clinical relevance of these findings. For example, these neutralizing antibodies recognize the V3 loop determinants of a single strain, and not conserved or discontinuous epitopes. Thus, these antibodies lack the ability to neutralize the broad spectrum of HIV-l strains present in an HIV-l population. Furthermore, the challenge virus was the homologous HIV-l laboratory adapted LAI (HTLV- IIIB) strain and not one of the primary isolates that contain considerable gpl20 sequence heterogeneity. Since these experiments showed that gpl20 subunit vaccination induces an immune response effective against only the homogeneous HIV-l strain used as an antigen, it is unlikely that the vaccination regimens used in these studies would be useful in humans.

Individuals infected by HIV-l typically develop antibodies that neutralize the virus in vitro, and neutralization titers decrease with disease progression (19) . Analysis of sera from HIV-l-infected humans indicates that type-specific neutralizing antibodies appear early in infection. Later in the course of infection, a more broadly neutralizing antibody response develops. However this antibody response is of significantly lower titer and/or affinity. Fractionation studies of HIV-l antibody-positive human sera reveal that the type-specific neutralizing activity is primarily directed against linear determinants in the V3 loop of gpl20 (20) . There was no correlation found among antibodies between the ability to neutralize divergent. HIV-1 isolates and reactivity to the V3 loop of these isolates. In contrast, the broadly neutralizing antibodies present in HIV-l antibody-positive human sera primarly recognize discontinuous epitopes in gpl20 which overlap the CD4- binding site and block gpl20-CD4 binding. In other words, the broadly neutralizing activity of neutralizing antibodies is not merely the result of additive anti-V3 loop reactivities against diverse HIV-l isolates which appear during infection.

Recently, several groups have generated human monoclonal antibodies (hMoAbs) derived from HIV-l infected individuals which possess type-specific or group-common neutralizing activities (17) . The type-specific neutralizing hMoAbs were found to recognize linear determinants in the V3 loop of gpl20. In contrast, the group-common neutralizing hMoAbs generally recognize discontinuous epitopes which overlap the CD4-binding site and block gpl20-CD4 binding.

The V3 loop is a highly immunodominant region of gpl20 which partially interacts with the CD4-binding region. The presence of the V3 loop region on gpl20 may skew the humoral immune response away from producing antibodies which specifically bind to the CD4-binding domain of gpl20. Furthermore, the advantages of removing the V3 loop to expose the CD4-binding domain of gpl20 to the immune system would be countered by the fact that the exposed CD4-binding site would still have a high affinity for cell surface CD4. In other words, a mutant gpl20 protein missing only the V3 loop would quickly bind to CD4+ cells and would thus be hampered in generating an immune response against the exposed CD4-binding site.

The subject invention provides a mutant HIV-l gpl20 envelope glycoprotein which overcomes both the problems of V3 -.loop immunodominance and of the high affinity to CD4. The subject invention further provides vaccines comprising the mutant HIV-l gpl20 envelope glycoprotein, antibodies which specifically bind to the CD4-binding site of HIV-l gpl20 envelope glycoprotein, pharmaceutical compositions comprising these antibodies, and methods of using these vaccines and compositions to treat or prevent HIV-l infection.

Summary of the Invention

The subject invention provides a recombinant nucleic acid molecule which encodes a mutant HIV-l gpl20 envelope glycoprotein comprising a V3 loop deletion and a C4 domain^.. _>X) point mutation, wherein X is an amino acid residue other than tryptophan. In the preferred embodiment, X is a valine residue.

In one embodiment, the nucleic acid molecule is a DNA molecule. The DNA molecule may be a plasmid. In one embodiment, the plasmid comprises the sequence of the plasmid designated PPI4-tPA.

In one embodiment, the C4 domain is an HIV-1^, gpl20 envelope glycoprotein C4 domain. The mutant HIV-l gpl20 envelope glycoprotein may be a mutant gpl20 envelope glycoprotein.

In another embodiment, the C4 domain is an HIV-I_JU._FL gpl20 envelope glycoprotein C4 domain. The mutant HIV-l gpl20 envelope glycoprotein may be a mutant HIV-l^.^ gpl20 envelope glycoprotein.

The subject invention also provides the mutant HIV-l gpl20 envelope glycoprotein encoded by the recombinant nucleic acid molecule of the subject invention.

The subject invention further provides a vaccine which comprises a therapeutically effective amount of the mutant HIV-l gpl20 envelope glycoprotein of the subject invention, and an adjuvant.

The subject invention further provides a method of treating an HIV-l-infected subject, which comprises immunizing the HIV-l-infected subject with the vaccine of the subject invention, thereby treating the HIV-l-infected subject.

The subject invention further provides a vaccine which comprises a prophylactically effective amount of the mutant HIV-l gpl20 envelope glycoprotein of the subject invention, and an adjuvant.

The subject invention further provides a method of reducing the likelihood of an HIV-l-exposed subject's becoming infected with HIV-l, which comprises immunizing the HIV-1- exposed subject with the vaccine of the subject invention, thereby reducing the likelihood of the HIV-l-exposed subject's becoming infected with HIV-l.

The subject invention further provides a method of reducing the likelihood of a non-HIV-l-exposed subject's becoming infected with HIV-l, which comprises immunizing the non-HIV- 1-exposed subject with the vaccine of the subject invention, thereby reducing the likelihood of the non-HIV-l-exposed subject's becoming infected with HIV-l.

The subject invention further provides a method of obtaining partially purified antibodies which specifically bind to the CD4-binding domain of HIV-l gpl20 envelope glycoprotein, which method comprises (a) immunizing a non-HIV-l-exposed subject with the vaccine of the subject invention, (b) recovering from the immunized subject serum comprising said antibodies, and (c) partially purifying said antibodies, thereby obtaining partially purified antibodies which specifically bind to the CD -binding domain of HIV-l gpl20 envelope glycoprotein. In the preferred embodiment, the subject is a human. The subject invention further provides the partially purified antibodies produced by the method of the subject invention.

The subject invention further provides a pharmaceutical composition, which comprises a therapeutically effective amount of the partially purified antibodies of the subject invention, and a pharmaceutically acceptable carrier.

The subject invention further provides a method of treating an HIV-l-infected subject, which comprises administering to the subject a dose of the pharmaceutical composition of the subject invention effective to reduce the population of HIV- l-infected cells in the HIV-l-infected subject, thereby treating the HIV-l-infected subject.

The subject invention further provides a method of treating an HIV-l-infected subject, which comprises administering to the subject a dose of the pharmaceutical composition of the subject invention effective to reduce the population of HIV- 1 in the HIV-l-infected subject, thereby treating the HIV-l- infected subject.

The subject invention further provides a composition which comprises a prophylactically effective amount of the partially purified antibodies of the subject invention, and a pharmaceutically acceptable carrier.

The subject invention further provides a method of reducing the likelihood of an HIV-l-exposed subject's becoming infected with HIV-l, which comprises administering to the HIV-l-exposed subject a dose of the composition of the subject invention effective to reduce the population of HIV- 1 in the HIV-l-exposed subject, thereby reducing the likelihood of the subject's becoming infected with HIV-l. In one embodiment, the subject is a medical practitioner. In another embodiment, the subject is a newborn infant.

Finally, the subject invention provides a method of reducing the likelihood of a non-HIV-1-exposed subject's becoming infected with HIV-l as a result of exposure thereto during an incident wherein there is an increased risk of exposure to HIV-l, which comprises administering to the subject immediately prior to the incident a dose of the composition of the subject invention effective to reduce the population of HIV-l to which the subject is exposed during the incident, thereby reducing the likelihood of the subject's becoming infected with HIV-l. In one embodiment, the subject is a medical practitioner.

Brief Description of the Figures

Figure 1 gpl20 structure. Shown is a box diagram of HIV-l gpl20 depicting the boundaries of the five constant domains. (Cl- C5) and the five variable domains (VI-V5) . The amino acid residue numbering above the box begins at the initiator methionine found at the beginning of the signal sequence (S) and is approximated based on a consensus of all known HIV-l gpl20 amino acid sequences. Also shown are the C4 domain amino acid sequences of HIV-l strains LAI and JR-FL. Above the C4 domain sequences are indicated two mutations that reduce gpl20 binding to cell surface CD4; tryptophan to valine and aspartate to alanine.

Figure 2

PPI4-tPA-gpl20_LΛI. Expression vector with the HIV-l,^ gpl20 gene fused to the CMV MIE promoter, and the tPA signal sequence replacing the HIV-l gpl20 signal sequence. Abbreviations: CMV MIE = cytomegalovirus major immediate early, E = enhancer, P = promoter, EXA = Exon A, INA = Intron A, EXB = Exon B, tPA ss = human tissue plasminogen activator signal sequence, gpl20 = glycoprotein 120, BGH = bovine growth hormone, AMP = ampicillin resistance gene, and DHFR = dihydrofolate reductase gene.

Figure 3

CMV MIE promoter fused to tPA-gpi20_T . The nucleotide sequence of the CMV MIE promoter/enhancer region is shown fused to the HIV-l,^ gpl20 gene that contains the tPA signal sequence. The numbering of nucleotide sequence begins with the Hindi site and the numbering of the amino acid sequence begins with the first methionine found in the tPA signal sequence. The tPA signal sequence is fused in-frame to Thr₃₁ of gpl20, the first amino acid found in mature gpl20. The signal sequence is shown in bold as are various landmark restriction sites used for cloning as discussed in the text. The locations of Exon A, Intron A, Exon B and the transcription start site and the signal cleavage site are indicated.

Figure 4

Transient expression of gp!20. Autoradiograph of ³⁵S-labeled supernatants from COS cell transfectants, immunoprecipitated with a CD4-immunoglobulin-Protein A-Sepharose complex, and run on a reducing 10% SDS-PAGE gel. The plasmids used for transfection were: Lane 1: Mock transfected cells; lane 2: a vector encoding a CD4-immunoglobulin chimera as a positive transfection control; lane 3: PPI4-tPA-gpl20_LAI; and lane 4: PPI4-tPA-gpl20j_R.p_L. Positions of molecular weight markers are indicated.

Figure 5 Determination of gpl20 concentration by ELISA. Panel A:

Concentrations of gpl20 in media of CHO cell lines, stably transfected with PPI4-tPA-gpl20_LAI, determined by ELISA.

Panel B: A standard curve was established using known amounts of gpl20.

Figure 6

Expression of gpl20 in stably transfected CHO cells.

Autoradiograph of ³⁵S-labeled supernatants from stable CHO cell lines, immunoprecipitated with a CD -immunoglobulin- Protein A-Sepharose complex, and run on a reducing 10% SDS-

PAGE gel. Lane 1: clone 9; lane 2: clone 13; lane 3: clone

6; lane 4: Clone 5. Positions of molecular weight markers are indicated. Figure 7 tPA-gpl20_TPFL. The nucleotide and deduced amino acid sequence of the tPA signal sequence fused to HIV-1_JR._FL gpl20 is shown. The Narl and NotI restriction endonuclease sites used for clcning are shown in bold. The predicted site of cleavage by signal peptidase between Arg_3J and Val₃₆ is indicated.

Figure 8 tPA-gpl20_LΛι-V3⁽'⁾. The nucleotide and deduced amino acid sequence of the tPA signal sequence fused to HIV-l^ gpl20 with the V3 loop deleted and replaced with the pentapeptide TGAGH is shown. The V3 loop replacement and the Narl and NotI restriction endonuclease sites used for cloning are shown in bold. The predicted site of cleavage by signal peptidase between Arg₃₅ and Thr₃₆ is indicated.

Figure 9 tPA-gpl20_TRFL-V3^('). The nucleotide and deduced amino acid sequence of the tPA signal sequence fused to HIV-1,_R._FL gpl20 with the V3 loop deleted and replaced with the pentapeptide TGAGH is shown. The V3 loop replacement and the Narl and NotI restriction endonuclease sites used for cloning are shown in bold. The predicted site of cleavage by signal peptidase between Arg₃₅ and Val₃₆ is indicated.

Figure 10 tPA-gpl20_LAI-V3^(')-CD4^('). Shown is the nucleotide and deduced amino acid sequence of the tPA signal sequence fused to HIV- iι__Ai gp!20, with the V3 loop deleted and replaced with the pentapeptide TGAGH, and mutated to Val. The mutations and the Narl and NotI restriction endonuclease sites used for cloning are shown in bold. The predicted site of cleavage by signal peptidase between Arg_3S and Thr₃₆ is indicated. Figure 11 PA-gpl20 _FL-V3^(')-CD4^('). Shown is the nucleotide and deduced amino acid sequence of the tPA signal sequence fused to HIV- 1_JR-_FL gP¹²⁰/ with the V3 loop deleted and replaced with the pentapeptide TGAGH, and Trp₃₉₆ mutated to Val. The mutations and the Narl and NotI restriction endonuclease sites used for cloning are shown in bold. The predicted site of cleavage by signal peptidase between Arg₃₅ and Val₃₆ is indicated.

Figure 12 tPA-gpl20_LΛI-CD4^(~). Shown is the nucleotide and deduced amino acid sequence of the tPA signal sequence fused to HIV-l^ gpl20. The Trp₄₃₇ to Val CD4 binding mutation, the Narl and NotI restriction endonuclease sites used for cloning, and the predicted site of cleavage by signal peptidase between Arg₃₅ and Thr₃₆ are shown in bold.

Figure 13 tPA-gp!2O_JRFL'CD4°. Shown is the nucleotide and deduced amino acid sequence of the tPA signal sequence fused to HIV-lτ_R-FL gpl20. The Trp₄₂ to Val CD4 binding mutation, the Narl and NotI restriction endonuclease sites used for cloning and the predicted cleavage by signal peptidase between Arg_3J and Val₃₆ are shown in bold.

Figure 14

Expression of gpl20 in stably transfected CHO cells. Autoradiograph of super ³⁵S-labeled supernatants from stable CHO cell lines, immunoprecipitated with MoAb F105-Protein A- Sepharose complex, and run on a reducing 10% SDS-PAGE gel. Panel A: Lane 1: tPA-gpl20_LAI CHO cells; lane 2: tPA-gpl20_LAI- V3^H CHO cells; lane 3: tPA-gpl20_LA V3⁽-⁾-CD4⁽-⁾ CHO cells. Panel B: Lane 1: tPA-gpl20_IR._FL CHO cells; lane 2: tPA-gpl20_JR-FL-V3⁽"⁾ CHO cells; lane 3: tPA-gpl20_JR._FL-V3⁽'^,-CD4⁽-⁾ CHO cells. Positions of molecular weight markers are indicated.

Figure 15 Purified gpl20 proteins.

Silver stained 10% SDS-PAGE gel with a sample of purified gpl20 proteins. Panel A: Lane l: tPA-gpl20_LAI CHO cells; lane 2: tPA-gpl20_LAI-V3⁽-⁾ CHO cells; lane 3: tPA-gpl20_LAI-V3^w-CD4⁽-⁾ CHO cells. Panel B: Lane 1: tPA-gpl20_TR-F CHO cells; lane 2: tPA-gpl20,_R._FL-V3⁽-⁾ CHO cells; lane 3: tPA-gpl20_JR._FL-V3⁽-'-CD4^(') CHO cells. Positions of molecular weight markers are indicated.

Figure 16

Analysis of binding of recombinant mutant gp!20 to cell surface human CD4 by FACS.

Plate 1. DG44 cells, a subclone of CHO cells which lack expression of the human CD4 protein, were used as control. Increasing concentrations of HIV-l gpl20_LAι did not show an increase in specific fluoresence when compared to background. Plate 2. DG44 #3 cells are a CHO cell line transfected with the cDNA clone encoding the human CD4 protein. Increasing concentrations of HIV-l gpl20_LAI show a dramatic increase (or shift) in fluoresence. Plate 3. Similar to Plate 2 but the HIV-l gp^O^-VS" protein was added. Again a large shift indicating binding to the DG44 #3 cells was seen. Plate 4. DG44 #3 cells were incubated with either HIV-l gpl20_LArV3^(')-CD4⁽-⁾ protein or MoAb 0KT4A an antibody with high affinity for human CD4. Only 0KT4A bound to the cells. Detailed Description of the Invention

The plasmids designated PPI4-tPA-gpl20_LAI and PPI4-tPA-gpl20_JR. _FL were deposited pursuant to, and in satisfaction of, the requirements of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure with the American Type Culture Collection (ATCC) , 12301 Parklawn Drive, Rockville, Maryland 20852 under ATCC Accession Nos. 75431 and 75432, respectively. The plasmids PPI4-tPA-gpl20_LAI and PPI4-tPA- gpl20_jR-FL were deposited with the ATCC on March 12, 1993.

The subject invention provides a recombinant nucleic acid molecule which encodes a mutant HIV-l gpl20 envelope glycoprotein comprising a V3 loop deletion and a C4 domain_(W_ _>X) point mutation, wherein X is an amino acid residue other than tryptophan. In the preferred embodiment, X is a valine residue.

The V3 loop of HIV-l gpl20 envelope glycoprotein is shown in Figure 1. The V3 loop is demarcated by cysteine residues at both its N- and C-termini. As used herein, a V3 loop deletion means a deletion of one or more amino acid residues between the terminal cysteine residues, with the proviso that there must be three or more amino acid residues situated between the two terminal cysteine residues in a V3 loop deletion. These three or more amino acid residues may either be residues originally present in the V3 loop, or exogenous residues. For example, as shown in the Experimental Details section infra, the pentapeptide TGAGH is situated between the two terminal cysteine residues. Variations in the size of the V3 loop deletion illustrated herein are tolerable without affecting the overall structure of the mutant HIV-l gpl20 envelope glycoprotein, as is -.well known to those skilled in the art.

As used herein, "C4 domain" means the HIV-l gpl20 envelope glycoprotein C4 domain having the following consensus sequence:

X₁X₂X₃CX₄IX₅X₆X₇X_gX₉X₁oWX_nX₁ Xι ι Xi₅AXι₆YX₁₇X₁₈- PXι₉X₂oX₂ιX₂₂X₂₃X₂X₂₅X₂₆S ₂₇X₂gTGX X₃oX₃₁X₂RX₃₃GX₃₄,

wherein X. = T, I, V, K or R; X₂ = L, I or H; X₃ = P, Q, L or T; X₄ = R, K or G; X₅ = K or E; X* = Q or E; X₇ = F, I or V; X₈ = I, V or M; X, = N, R or K; X₁₀ = M, R, L or T; X_n = Q, R or V; X,₂ = E, K, G, R, V or A; X₁₃ = V, T, A or G; X₁₄ = G or E; X₁₅ = K, R, E, or Q; X₁₆ = M, V, I or L; X₁₇ = A, T or D; X₁₈ = P or L; X_t9 = I or F; X₂₀ = S, R, G, K, N, A, E or Q; X₂₁ = G or R; X₂₂ = Q, L, P, N, K, V, T, E or I; X^ = I, V or L; X_M = R, K, S, N, G, I, T, E or I; X^ = C or R; X₂₆ = S, L, I, T, P, E, V, K, D or N; „ = N, K or L; X_2g = I or V; X₂₉ = L, P or I; X₃₀ = L or I; X₃₁ = L or I; X₃₂ = T, A, I, V or E; X₃₃ = D or E; X_M = G or V.

The C4 domain consensus sequence is based on existing C4 domain sequence information from various HIV-l strains, and thus is not necessarily an exhaustive consensus sequence. The conserved tryptophan residue shown in bold after residue Xio is the only conserved tryptophan residue in the C4 domain. As used herein, a C4 domain_(W__>X) point mutation is a mutation of the above-identified conserved C4 domain tryptophan residue to an amino acid residue other than tryptophan. For example, a C4 domain_(W.__>V) point mutation is a mutation of the conserved C4 domain tryptophan residue to a valine residue.

In one embodiment, the C4 domain is an HIV-l^i gpl20 envelope glycoprotein C4 domain. The sequence of the HIV- I_LAI g l20 C4 domain is: TLPCRI QFINMWQEVGKAMYAPPISGQIRCS- SNITGLLLTRDGG. The mutant HIV-l gpl20 envelope glycoprotein may be a mutant HIV-l^ gpl20 envelope glycoprotein.

In another embodiment, the C4 domain is an HIV-I_JR.^ gpl20 envelope glycoprotein C4 domain. The sequence of the HIV-1_JR. _FL gpl20 C4 domain is: TLPCRIKQIINMWQEVGKAMYAPPIRGQIRCS- SNITGLLLTRDGG. The mutant HIV-l gpl20 envelope glycoprotein may be a mutant HIV-lj_R-FL gpl20 envelope glycoprotein.

HIV-I_LAJ is a laboratory-adapted strain that is tropic for phytohemagglutinin (PHA) -stimulated peripheral blood lymphocytes (PBLs) and immortalized human T-cell lines. In contrast, HIV-l_ra-FL was isolated from brain tissue taken at autopsy that was co-cultured with lectin-activated normal human PBLs. HIV-1_JR._FL is tropic for PHA-stimulated PBLs and blood-derived macrophages but will not replicate in transformed T-cell lines. Mutant HIV-l gpl20 envelope glycoproteins derived from a clinical isolate of HIV-l such as JR-FL may possess new or different epitopes compared to the laboratory-adapted HIV-l strains that are beneficial for successful vaccination. Although only the HIV-l^ and HIV- -L_JR-_FL strains are used herein to generate the mutant HIV-l gpl20 envelope glycoproteins of the subject invention, other HIV-l strain could be substituted in their place as is well known to those skilled in the art.

The VI and V2 variable regions of gpl20 are unnecessary for CD4 binding (21) . Therefore the mutant HIV-l gpl20 envelope glycoprotein of this invention can either include or exclude the VI and V2 variable regions.

The subject invention additionally provides a recombinant nucleic acid molecule which encodes a mutant HIV-l gpi20 envelope glycoprotein comprising a V3 loop deletion and a C4 domain_(Asp__>X) point mutation, wherein the aspartate residue is between amino acid residues X₁₅ and X_t6 in the C4 consensus sequence, and X is an amino acid residue other than aspartate or glutamate. In the preferred embodiment, X is an alanine residue.

The subject invention additionally provides a recombinant nucleic acid molecule which encodes a mutant HIV-l gpi20 envelope glycoprotein comprising a V3 loop deletion and a C4 domain_(Ghl__>X) point mutation, wherein the glutamate residue is between amino acid residues X₁₅ and X₁₆ in the C4 consensus sequence, and X is an amino acid residue other than aspartate or glutamate. In the preferred embodiment, X is an alanine residue.

The subject invention additionally provides a recombinant nucleic acid molecule which encodes a mutant HIV-l^ gpl20 envelope glycoprotein comprising a V3 loop deletion and a C3 domain_(Mp378__>X) point mutation, wherein X is an amino acid residue other than aspartate or glutamate. In the preferred embodiment, X is a lysine residue.

The subject invention additionally provides a recombinant nucleic acid molecule which encodes a mutant HIV-1_JR-FL gpl20 envelope glycoprotein comprising a V3 loop deletion and a C3 domain_(ωp369__>X) point mutation, wherein X is an amino acid residue other than aspartate or glutamate. In the preferred embodiment, X is a lysine residue.

The subject invention additionally provides a recombinant nucleic acid molecule which encodes a mutant HIV-l^, gpl20 envelope glycoprotein comprising a V3 loop deletion and:a C3 domain_(glu3g0-->X) point mutation, wherein X is an amino acid residue other than glutamate. In the preferred embodiment, X is a glut mine residue.

The subject invention additionally provides a recombinant nucleic acid molecule which encodes a mutant HIV-I_JR.^ gpl20 envelope glycoprotein comprising a V3 loop deletion and a C3 domain_(glu371__>X) point mutation, wherein X is an amino acid residue other than glutamate. In the preferred embodiment, X is a glutamine residue.

The subject invention additionally provides a recombinant nucleic acid molecule which encodes a mutant HIV-l^ gpl20 envelope glycoprotein comprising a V3 loop deletion and a C2 domain_(thr267__>X) point mutation, wherein X is an amino acid residue other than threonine. In the preferred embodiment, X is an arginine residue.

The subject invention additionally provides a recombinant nucleic acid molecule which encodes a mutant HIV-l_rR._FL gpl20 envelope glycoprotein comprising a V3 loop deletion and a C2 domain_(thl26o__>X) point mutation, wherein X is an amino acid residue other than threonine. In the preferred embodiment, X is an arginine residue.

The subject invention additionally provides a recombinant nucleic acid molecule which encodes a mutant HIV-l gpl20 envelope glycoprotein comprising (a) a V3 loop deletion, or (b) a one of the C2, C3 or C4 domain point mutations discussed supra.

The point mutations in the recombinant nucleic acid molecules described supra are selected based on their ability to reduce the affinity of the mutant gpl20 glycoprotein encoded thereby for CD4. As used herein, the term "reduce the affinity" means to reduce the affinity by at least two-fold.

One skilled in the art would know how to make recombinant nucleic acid molecules which encode mutant HIV-l gpl20 envelope glycoproteins comprising a V3 loop deletion and the specific C2, C3 or C4 domain point mutations corresponding to those mutations exemplified in the HIV-I_JR._FL and HIV-l^ strains, supra. Furthermore, one skilled in the art would know how to use these recombinant nucleic acid molecules to obtain the proteins encoded thereby, and practice the therapeutic and prophylactic methods of using same, as described herein for the recombinant nucleic acid molecule which encodes a mutant HIV-l gpl20 envelope glycoprotein comprising a V3 loop deletion and a C4 domain_(W__>X) point mutation.

In accordance with the invention, numerous vector systems for expression of the mutant HIV-l gpl20 envelope glycoprotein may be employed. For example, one class of vectors utilizes DNA elements which are derived from animal viruses such as bovine papilloma virus, polyoma virus, adenovirus, vaccinia virus, baculovirus, retroviruses (RSV, MMTV or MoMLV) , Semliki Forest virus or SV40 virus. Additionally, cells which have stably integrated the DNA into their chromosomes may be selected by introducing one or more markers which allow for the selection of transfected host cells. The marker may provide, for example, prototropy to an auxotrophic host, biocide resistance, (e.g., antibiotics) or resistance to heavy metals such as copper or the like. The selectable marker gene can be either directly linked to the DNA sequences to be expressed, or introduced into the same cell by cotransformation. Additional elements may also be needed for optimal synthesis of mRNA. These elements may include splice signals, as well as transcriptional promoters, enhancers, and termination signals. The cDNA expression vectors incorporating such elements include those described by Okayama (22) .

The vectors used in the subject invention are designed to express high levels of mutant HIV-l gpl20 envelope glycoproteins in cultured eukaryotic cells as well as efficiently secrete these proteins into the culture medium. The targeting of the mutant HIV-l gpl20 envelope glycoproteins into the culture medium is accomplished by fusing in-frame to the mature N-terminus of the mutant HIV-l gpl20 envelope glycoprotein the tissue plasminogen activator (tPA) prepro-signal sequence.

The mutant HIV-l gpl20 envelope glycoprotein may be produced by a) transfecting a mammalian cell with an expression vector for producing mutant HIV-l gpl20 envelope glycoprotein; b) culturing the resulting transfected mammalian cell under conditions such that mutant HIV-l gpl20 envelope glycoprotein is produced; and c) recovering the mutant HIV-l gpl20 envelope glycoprotein so produced.

Once the expression vector or DNA sequence containing the constructs has been prepared for expression, the expression vectors may be transfected or introduced into an appropriate mammalian cell host. Various techniques may be employed to achieve this, such as, for example, protoplast fusion, calcium phosphate precipitation, electroporation or other conventional techniques. In the case of protoplast fusion, the cells are grown in media and screened for the appropriate activity. Expression of the gene encoding a mutant HIV-l gpl20 envelope glycoprotein results in production of the mutant glycoprotein.

Methods and conditions for culturing the resulting transfected cells and for recovering the mutant HIV-l gpl20 envelope glycoprotein so produced are well known to those skilled in the art, and may be varied or optimized depending upon the specific expression vector and mammalian host cell employed.

In accordance with the claimed invention, the preferred host cells for expressing the mutant HIV-l gpl20 envelope glycoprotein of this invention are mammalian cell lines. Mammalian cell lines include, for example, monkey kidney CVl line transformed by SV40 (COS-7) ; human embryonic kidney line 293; baby hamster kidney cells (BHK) ; Chinese hamster ovary-cells-DHFR (CHO) ; Chinese hamster ovary-cells DHFR" (DXBll) ; monkey kidney cells (CVl) ; African green monkey kidney cells (VERO-76) ; human cervical carcinoma cells (HELA) ; canine kidney cells (MDCK) ; human lung cells (W138) ; human liver cells (Hep G2) ; mouse mammary tumor (MMT 060562); mouse cell line (C127) ; and myeloma cell lines.

Other eukaryotic expression systems utilizing non-mammalian vector/cell line combinations can be used to produce the mutant HIV-l gpl20 envelope glycoproteins. These include, but are not limited to, baculovirus vector/insect cell expression systems and yeast shuttle vector/yeast cell expression systems.

Methods and conditions for purifying mutant HIV-l gpl20 envelope glycoproteins from the culture media are provided in the invention, but it should be recognized that these procedures can be varied or optimized as is well known to those skilled in the art.

A therapeutically effective amount of the mutant HIV-l gpl20 envelope glycoprotein may be determined according to methods well known to those skilled in the art.

As used herein, adjuvants include, but are not limited to, alum, Freund's incomplete adjuvant (FIA) , Saponin, Quil A, Monophosphoryl lipid A (MPL) , and nonionic block copolymers (SAF) such as L-121 (Pluronic; Syntex SAF) . In the preferred embodiment, the adjuvant is alum, especially in the form of a thixotropic, viscous, and homogeneous aluminum hydroxide gel. The vaccine of the subject invention may be administered as an oil in water emulsion. Methods of combining adjuvants with antigens are well known to those skilled in the art.

As used herein, treating an HIV-l-infected subject with the vaccine of the subject invention means reducing in the subject either the population of HIV-l or HIV-l-infected cells, or ameliorating the progression of an HIV-l-related disorder in the subject.

As used herein, an "HIV-infected subject" means an individual having at least one of his own cells invaded by HIV-l.

As used herein, "immunizing" means administering a primary dose of the vaccine to a subject, followed after a suitable period of time by one or more subsequent administrations of the vaccine, so as to generate in the subject an immune response against the CD4-binding region of the mutant HIV-l gpl20 envelope glycoprotein in the vaccine. A suitable period of time between administrations of the vaccine may readily be determined by one skilled in the art, and is usually in the order of several weeks to months.

In the preferred embodiment, the dose of vaccine administered is an amount sufficient to deliver to the subject between lOug and lmg of the mutant HIV-l gpl20 envelope glycoprotein.

A prophylactically effective amount of the mutant HIV-l gpl20 envelope glycoprotein may be determined according to methods well known to those skilled in the art.

The subject invention further provides a method of reducing the likelihood of an HIV-1-exposed subject's becoming infected with HIV-l, which comprises immunizing the HIV-l- exposed subject with the vaccine of the subject invention, thereby reducing the likelihood of the HIV-l-exposed subject's becoming infected with HIV-l.

As used herein, the subject's becoming infected with HIV-l means the invasion of the subject's own cells by HIV-l.

As used herein, reducing the likelihood of a subject's becoming infected with HIV-l means reducing the likelihood of the subject's becoming infected with HIV-l by at least two-fold. For example, if a subject has a 1% chance of becoming infected with HIV-l, a two-fold reduction in the likelihood of the subject's becoming infected with HIV-l would result in the subject's having a 0.5% chance of becoming infected with HIV-l. In the preferred embodiment of this invention, reducing the likelihood of the subject's becoming infected with HIV-l means reducing the likelihood of the subject's becoming infected with HIV-l by at least ten-fold.

As used herein, an HIV-l-exposed subject is a subject who has HIV-l present in his body, but has not yet become HIV-1- infected.

As used herein, a non-HIV-l-exposed subject is a subject who does not have HIV-l present in his body. The subject invention further provides a method of obtaining partially purified antibodies which specifically bind to the CD4-binding domain of HIV-l gpl20 envelope glycoprotein, which method comprises (a) immunizing a non-HIV-l-exposed subject with the vaccine of the subject invention, (b) recovering from the immunized subject serum comprising said antibodies, and (c) partially purifying said antibodies, thereby obtaining partially purified antibodies which specifically bind to the CD4-binding domain of HIV-l gpl20 envelope glycoprotein. In the preferred embodiment, the subject is a human.

As used herein, partially purified antibodies means a composition which comprises antibodies which specifically bind to the CD4-binding domain of HIV-l gpl20 envelope glycoprotein, and consists of fewer protein impurities than does the serum from which the anti-CD4-binding domain antibodies are derived. A protein impurity means a protein other than the anti-CD4-binding domain antibodies. For example, the partially purified antibodies might be an IgG preparation.

Methods of recovering serum from a subject are well known to those skilled in the art. Methods of partially purifying antibodies are also well known to those skilled in the art, and include, by way of example, filtration, ion exchange chromatography, and precipitation.

In one embodiment, the partially purified antibodies comprise an immune globulin (IG) preparation. IG can be purified from serum by a two-step process. Initially, serum is fractionated by the cold ethanol method of Co n, et al.

(29) . Co n Fraction II has as its main protein component

IgG immunoglobulin present as monomers, dimers and aggregates. Fraction II is then purified to produce IVIG (immune globulin intravenous) using a variety of purification methods which include, for example, ion exchange, DEAE chromatography, acid pH 4.25 diafiltration, PEG precipitation or Pepsin treatment. The final product is stabilized (e.g., glucose + NaCl) and the final- IgG concentration is fixed at between about 3% and about 6%.

The subject invention further provides the partially purified antibodies produced by the method of the subject invention.

A therapeutically effective amount of the partially purified antibodies of the subject invention may be determined according to methods well known to those skilled in the art.

Pharmaceutically acceptable carriers are well known to those skilled in the art and include, but are not limited to, 0.01-O.lM and preferably 0.05M phosphate buffer or 0.8% saline. Additionally, such pharmaceutically acceptable carriers may be aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media. Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's or fixed oils. Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers such as those based on Ringer's dextrose, and the like. Preserva¬ tives and other additives may also be present, such as, for example, antimicrobials, antioxidants, chelating agents, inert gases and the like.

The subject invention further provides a method of treating an HIV-l-infected subject, which comprises administering to the subject a dose of the pharmaceutical composition of the subject invention ef-fective to reduce the population of HIV- 1-infected cells in the HIV-l-infected subject, thereby treating the HIV-l-infected subject.

As used herein, administering may be effected or performed using any of the various methods known to those skilled in the art. The administering may comprise administering intravenously. The administering may also comprise administering intramuscularly. The administering may further comprise administering subcutaneously.

The dose of the pharmaceutical composition of the subject invention effective to reduce the population of HIV-1- infected cells in the HIV-l-infected subject may be readily determined using methods well known to those skilled in the art. In the preferred embodiment, the dose is sufficient to deliver to the subject between about 10 mg/kg and 150mg/kg of protein if administered intramuscularly. In the preferred embodiment, the dose is sufficient to deliver to the subject between about 100 mg/kg and 2g/kg of protein if administered intravenously.

The dose of the pharmaceutical composition of the subject invention effective to reduce the population of HIV-l in the HIV-l-infected subject may be readily determined .using methods well known to those skilled in the art. In the preferred embodiment, the dose is sufficient to deliver to the subject between about 10 mg/kg and 150mg/kg of protein if administered intramuscularly. In the preferred embodiment, the dose is sufficient to deliver to the subject between about 100 mg/kg and 2g/kg of protein if administered intravenously.

A prophylactically effective amount of the partially purified antibodies of the subject invention may be determined according to methods well known to those skilled in the art.

The subject invention further provides a method of reducing the likelihood of an HIV-1-exposed subject's becoming infected with HIV-l, which comprises administering to the HIV-l-exposed subject a dose of the composition of the subject invention effective to reduce the population of HIV- 1 in the HIV-l-exposed subject, thereby reducing the likelihood of the subject's becoming infected with HIV-l.

In one embodiment, the subject is a medical practitioner.

The medical practitioner may be . a medical practitioner exposed to an HIV-l-containing bodily fluid. As used herein, the term "medical practitioner" includes, but is in no way limited to, doctors, dentists, surgeons, nurses, medical laboratory assistants, and students in health care programs.

In another embodiment, the subject is a newborn infant. The newborn infant may be a newborn infant born to an HIV-l- infected mother.

The dose of the composition of the subject invention effective to reduce the population of HIV-l in the HIV-1- exposed subject may be readily determined using methods well known to those skilled in the art. In the preferred embodiment, the dose is sufficient to deliver to the subject between about lOmg/kg and 150mg/kg of protein if administered intramuscularly. In the preferred embodiment, the dose is sufficient to deliver to the subject between about 100 mg/kg and 2g/kg of protein if administered intravenously.

The vaccines and pharmaceutical compositions of the subject invention may also ameliorate the progression of an HIV-l- related disorder in a subject to whom the vaccines or pharmaceutical compositions were administered while the subject was either non-HIV-l-exposed or HIV-l-exposed, but not yet HIV-l-infected.

Finally, the subject invention provides a method of reducing the likelihood of a non-HIV-l-exposed subject's becoming infected with HIV-l as a result of exposure thereto during an incident wherein there is an increased risk of exposure to HIV-l, which comprises administering to the subject immediately prior to the incident a dose of the composition of the subject invention effective to reduce the population of HIV-l to which the subject is exposed during the incident, thereby reducing the likelihood of the subject's becoming infected with HIV-l. In one embodiment, the subject is a medical practitioner.

An incident wherein there is an increased risk of exposure to HIV-l includes, for example, receiving a blood transfusion, sexual contact with an HIV-l-infected individual, and performing a HIV-l-containing bodily fluid- exposing medical procedure.

As used herein, "immediately prior to the incident" means within one month of the incident. In the preferred embodiment, "immediately prior to the incident" means within one day of the incident.

The dose of the composition of the subject invention effective to reduce the population of HIV-l to which the subject is exposed during the incident may be readily determined using methods well known to those skilled in the art. In the preferred embodiment, the dose is sufficient to deliver to the subject between about lOmg/kg and 150mg/kg of protein if administered intramuscularly. In the preferred embodiment, the dose is sufficient to deliver to the subject between about lOOmg/kg and 2g/kg of protein if administered intravenously.

One embodiment of this invention is a method of substantially reducing the likelihood of a non-infected medical practitioner's becoming infected with HIV-l during a bodily fluid-exposing medical procedure involving a patient, which comprises administering to the patient during a suitable time period an amount of the composition of the subject invention effective to substantially reduce the likelihood of the non-infected medical practitioner's becoming infected with HIV-l by virtue of contact with the patient's bodily fluid during the medical procedure. As used herein, a bodily fluid is any fluid which is present in the human body and is capable of containing infectious HIV-l in an HIV-l-infected patient. Bodily fluids include, but are not limited to, saliva, cerebrospinal fluid, tears, vaginal secretions, urine, alveolar fluid, synovial fluid and pleural fluid.

Another embodiment of this invention is a method of substantially reducing the likelihood of a non-HIV-i- infected newborn infant's becoming infected with HIV-l prior to or during birth from an HIV-l-infected mother, which comprises administering to the mother prior to birth an amount of the composition of the subject invention effective to substantially reduce the likelihood of the non-HIV-l- infected newborn infant's becoming infected with HIV-l by virtue of contact with the patient's bodily fluid.

In order to facilitate an understanding of the Experimental Details section which follows, certain frequently occurring methods and/or terms are best described in Maniatis et al. (23).

This invention will be better understood by reference to the Experimental Details which follow, but those skilled in the art will readily appreciate that the specific experiments detailed are only illustrative of the invention as described more fully in the claims which follow thereafter.

Experimental Details

Nomenclature

As used herein, V3° indicates a V3 loop deletion from HIV-l gpl20 envelope glycoprotein. As used herein, CD4 indicates a point mutation in the C4 domain of HIV-l gpl20 envelope glycoprotein which mutation inhibits CD4 binding to the mutant HIV-l gpl20 envelope glycoprotein. The structure of HIV-l gpl20 envelope glycoprotein is shown in Figure 1. Materials and Methods

1• Construction of PPI4-tPA-gp!20_LΛI expression vector. An expression vector was constructed that consisted of the cytomegalovirus major immediate early (CMV MIE) promoter/enhancer linked to the HIV-l_LAjejnv gene, which gene had its signal sequence replaced by the tPA signal sequence. The CMV MIE promoter/enhancer sequences were derived from pSVCCl (24) consisting of 1580 base pairs of contiguous DNA that is immediately 5' to the initiator ATG. In sequential order, the functional domains of the CMV promoter are: the promoter/enhancer region; a transcriptional initiator site; exon A (a non-coding exon) ; intron A; and 17 nucleotides of exon B (non-coding sequences) . The viral promoter sequences were ligated to a gene construct consisting of the nucleotide sequences encoding amino acids -35 to -1 of human tPA (25) fused in-frame to HIV-l_LΛIenv amino acids 31 through 515, ending with a TGA stop codon. The construction was performed in two parts. The majority of the CMV promoter could be isolated as a 1560 bp Hinc II/Pst I fragment which was ligated to a Pst I/Not I 1590 bp DNA fragment that contained the remainder of the CMV promoter, the initiator ATG, the tPA signal sequence and the mature HIV-l^ env protein coding sequence. The latter fragment was assembled using the polymerase chain reaction as follows. Primer 1 (GATCCTGCAGTCACCGTCCTTGACA- CGATGGATGCAATGAAGAGA) and primer 2 (AAGTCTTCTCCTCGGTCTTGT- CTTTTTAACACCCAG) were used to amplify the nucleic acid sequences encoding the tPA signal sequence amino acids -35 to -1 from plasmid pMAM neo-s (Clonetech) , thus producing a 150 bp fragment. A second 1440 bp DNA fragment was amplified using primer 3 (TTCAGAAGAGGAGCCAGAACAGAAAAATTGTGGGTC) , primer 4 (GGAAAAAAGCGGCCGCTCATTTTTCTCTCTGCACCACTC) , andpENV (26) as a template. The PCR fragments were pooled, desalted, and excess primer removed by ultrafiltration through a centricon-100 unit (Amicon) . An aliquot of the pooled material was then subjected to a second round of amplification in the presence of primers 1 and 4 to produce a 1590 bp fragment, which was then digested with Pst I and Not I. The CMV promoter fragment and the HIV-1^ env fragment were then ligated together, and the entire transcription unit subcloned into PPI4, which is a eukaryotic shuttle vector that contains an ampicillin resistance gene, an SV40 origin of replication and a DHFR gene whose transcription is driven by the β-globin promoter. The final construct, PPI4-tPA-gpl20_LAι, is shown in Figure 2.

The expression vector is then used as the prototype vector for the expression of gpl20 proteins that are derived from other HIV-l strains or mutated as described in the methods section. The vector was constructed so that unique Nar I and Not I sites flank the gpl20 sequence, thus facilitating the removal of the gpl20 gene cassette and the subsequent insertion of other gene cassettes (Figure 2) .

2. Expression of HIV-l^gp!20 in mammalian cells. a. Transient expression.

CosM5 cells grown in DMEM containing 10% fetal calf serum were split to 75% confluence. On the following day, the cells were transfected for 16-20 hours with 10 micrograms of CsCl-purified PPI4-tPA-gpl20_LAI DNA by the standard CaP0₄ (5) precipitation technique. After transfection, fresh medium was added to the cells. Analysis of the products synthesized 96-120 hours post-transfection was performed by radiolabelling the transfectants with ³⁵S-cysteine for 12-18 hours, followed by precipitation of media using a CD4- immunoglobulin-ProteinA-Sepharose complex, followed by SDS- PAGE under reducing conditions (Figure 4) .

b. Stable expression.

Dhfr^" Chinese hamster ovary cells (CHO) were transfected with 20 micrograms of CsCl-purified DNA. Approximately 3-5 days post-transfection, cells were placed in selective medium (nucleoside-free alpha MEM containing 10% dialyzed fetal calf serum) . Approximately 10-15 days post-selection, individual cell clones were picked. Media was analyzed for gpl20 expression by radiolabelling the cells with ³⁵S- cysteine for 12-18 hours, followed by precipitation of media using a CD4-immunoglobulin-Protein A-Sepharose complex, followed in turn by SDS-PAGE under reducing conditions (Figure 6) . The levels of gpl20 in the media of these clones were also quantitated (Figure 5) by ELISA performed as follows. The method involves coating 96-well plates overnight with sheep polyclonal IgG against the highly conserved C-terminus of gpl20 (D7234, Aalto Bioreagents) . After washing, dilutions of a standard gpl20 preparation in cell growth medium, or supernatant from the stably- transfected cells, were incubated for l hour. The plates were washed again, and incubated for one hour with a horseradish peroxidase-conjugated anti-gpl20 monoclonal antibody (9204, DuPont) . Following a final wash, the peroxidase substrate OPD (DuPont) was added and the amount of gpl20 determined by comparing absorbance of unknowns with a standard curve. Standards were prepared from purified gpl20 made in CHO cells, a small quantity of which was obtained from Celltech Ltd. Clones expressing the highest levels were subjected to successive rounds of amplification of the newly introduced DNA sequences in increasing concentrations of methotrexate. Stable CHO cell lines were thus generated which secrete at least 1 microgram/milliliter of HIV-I_LAJ gpl20.

3. Construction of PPI4-tPA-gpl20_mFL a. The HIV-I_LA! gpl20 env nucleotide sequence in PPI4-tPA- gpl20_LAI was replaced by the nucleotide sequence encoding the mature gpl20j_R.p_L protein. Using the polymerase chain reaction, the JR-FL sequences were amplified from pUC112-l

(27) using primer 5 (GATCGGCGCCAGAGTAGAAAAGTTGTGGGTCAC) and primer 4. The PCR fragment was digested with the restriction endonucleases Nar I and Not I, and the fragment subcloned in between the Nar I and Not I sites in PPI4-tPA- gpl20_LAi to generate PPI4-tPA-gpl20_JR._PL (Figure 7) .

b. Transient expression.

CosM5 cells grown in DMEM containing 10% fetal calf serum were split to 75% confluence. On the following day, the cells were transfected for 16-20 hours with 10 micrograms of CsCl-purified PPI4-tPA-gpl20_JR.p_L DNA by the standard CaP0₄ (5) precipitation technique. After transfection, fresh medium was added to the cells. Analysis of the products synthesized 96-120 hours post-transfection was performed by radiolabelling the transfectants with ³⁵S-cysteine for 12-18 hours, followed by precipitation of media using a CD4- immunoglobulin-Protein A-Sepharose complex, followed by SDS- PAGE under reducing conditions (Figure 4) . 4. Construction of PPI4-tPA-gpl20_L^-V3^H.

The V3 loop in tPA-gpl20_LAI consists of amino acids Cys₃₀₆ through Cys₃₃₃. In the V3^ri mutant, the amino acids in between these cysteines are replaced by the pentapeptide sequence Thr-Gly-Ala-Gly-His. Using the Transformer Site- Directed Mutagenesis Kit (Clonetech) , the V3 loop sequence in PPI4-tPA-gpl2θ_LAi is altered using the mutagenic primer 6 (CTGTAGAAATTAATTGTACAGGTGCTGGACATTGTAACATTAGTAGAGC) and primer 7 (CTCGAGCATGCATTCGAAGCTCGCTGATC) as a selection primer. Primer 7 changes a unique Xba I site in the backbone of the parent PPI4 plasmid into a unique BstB I site. Briefly, the mutagenesis method requires incubating of the parent plasmid with the mutagenic primer and the selection primer, denaturing at 100°C for 3 minutes and then chilling on ice. In the presence of buffered deoxynucleo- tide triphosphates and T4 DNA polymerase, the primers are allowed to initiate the polymerization of one strand of plasmid DNA. T4 DNA ligase is used to seal the newly synthesized DNA strand to form a covalently closed circle. Hybrid plasmids are then transformed into a MutS strain of E. coli that is deficient in mismatch repair. After allowing for the growth of transformed cells, DNA is purified from the cells and digested with the selection restriction endonuclease, in this case Xba I. Parental plasmids are cleaved by Xba I while the mutant plasmid remains resistant to cleavage by virtue of the Xba I to BstB I conversion. Digested DNA is then used to transform E. coli. and colonies harboring the mutant plasmid are picked. Multiple mutagenic primers can be used in a single round of mutagenesis. The amino acid sequence of the modified protein is shown in Figure 8.

5 . Construction of PPI4 - tPA-gpl20_{m FL}-V3⁽'⁾ .

The V3 loop in tPA-gpl20_JR._PL consists of amino acids Cys ₉₃ through Cys₃₂₇. In the V3^H mutant, the amino acids in between these cysteines are replaced by the pentapeptide sequence Thr-Gly-Ala-Gly-His. Using the Transformer Site- Directed Mutagenesis Kit (Clonetech) , the V3 loop sequence in PPI4- PA-gpl20j_R._FL is altered using the mutagenic primer 6 (CTGTAGAAATTAATTGTACAGGTGCTGGACATTGTAACATTAGTAGAGC) and primer 7 as a selection primer. The amino acid sequence of the modified protein is shown in Figure 9.

6. Construction of PPI4-tPA-gpl20_LΛI-CD4^(').

Using the Transformer Site-Directed Mutagenesis Kit

(Clonetech) , the selection primer 7, and the mutagenic primer 8 (CAATTTATAAACATGGTGCAGGAAGTAGG) , Trp₄₃₇ of tPA- gpl20_LAI, which is in an equivalent position to the tryptophan residue in the HXBc2 strain of HIV-l, is mutated to a Val in the expression vector PPI4-tPA-gpl2θ_LAi to generate PPI4-tPA-gpl20_LAI-CD4⁽"⁾. The sequence for gpl20_LAI- CD4^W is shown in Figure 12.

7. Construction of PPI4-tPA-gpl20_JRFL-CD4 .

In a fashion similar to that described above, Trp₄₂₄ of tPA- gpl20j_R.p_L is mutated to a Val in the expression vector PPI4- tPA-gpl20j_R.p_L using the selection primer 7 and the mutagenic primer 9 (CAAATTATAAACATGGTGCAGGAAGTAGG) to generate PPI4- tPA-gpl20j_R.p_L-CD4^("). The sequence for gpl20_JR._PL-CD4^W is shown in Figure 13.

8. Construction of PPI4-tPA-gpi20_LM-V3-⁾-CD4⁽-⁾. The tPA-gpl20_LAI double mutant, V3^(")-CD4^("), is constructed by including the mutagenic primers 6 and 8, and the selection primer 7 simultaneously in the reaction tube with PPI4-tPA- gpl20_LAi as the DNA template. The final construct is named PPI4-tPA-gpl20_LAI-V3^(")-CD4^("), and its sequence is shown in figure 10. 9 . Construction of PPI4 - tPA-gpl20_{m FL}-V3^(')- CD4⁽-⁾ .

The tPA-gpl20j_R._FL double mutant, V3^(")-CD4^("), is constructed by including the mutagenic primers 6 and 9, and the selection primer 7 simultaneously in the reaction tube with PPI4-tPA- gpl20_JR._FL as the DNA template. The final construct is named PPI4-tPA-gpl20j_R._FL-V3^(")-CD4⁽"⁾, and its sequence is shown in figure 11.

10. Expression of mutant HIV-l gpl20 in mammalian cells. a. Transient expression.

CosM5 cells grown in DMEM containing 10% fetal calf serum are split to 75% confluence. On the next day, the cells are transfected for 16-20 hours with 10 micrograms of CsCl- purified mutant HIV-l DNA by the standard CaP0₄ (5) precipitation technique. After transfection, fresh medium is added to the cells. Analysis of the products synthesized 96-120 hours post-transfection is performed by radiolabelling the transfectants with ³⁵S-cysteine for 12-18 hours, followed by precipitation of media using a sheep polyclonal IgG against the highly conserved C-terminus of gpl20.

b. Stable expression.

Dhfr^" Chinese hamster ovary cells (CHO) are transfected with 20 micrograms of CsCl-purified DNA encoding the native or mutant HIV-l gpl20 glycoproteins. Approximately 3-5 days post-transfection, cells are placed in selective medium

(nucleoside-free alpha MEM containing 10% dialyzed fetal calf serum) . Approximately 10-15 days post-selection, individual cell clones are picked. Media is analyzed for gpl20 expression by radiolabelling the cells with ³⁵S- cysteine for 12-18 hours, followed by quantitative immunoprecipitation of media using a sheep polyclonal IgG against the highly conserved C-terminus of gpl20, followed in turn by SDS-PAGE under reducing conditions. Alternatively, one can quantitate the level of gpl20 by ELISA performed as follows. The method involves coating 96- well plates overnight with sheep polyclonal IgG against the highly conserved C- erminus of gpl20 (D7234, Aalto Bioreagents) . After washing, dilutions of a standard gpl20 preparation in cell growth medium, or supernatant from the stably-transfected cells, are incubated for 1 hour. The plates are washed again, and incubated for one hour with a human MoAb (F105, AIDS Research & Reference Reagent Program, No. 857) . The plates are washed again, and incubated again for 1 hour with a horseradish-peroxidase-conjugated goat anti-human IgG (Cappel) . Following a final wash, the peroxidase substrate OPD (DuPont) is added and the amount of gpl20 determined by comparing absorbance of unknowns with a standard curve. Standards are prepared from purified gpl20 made in CHO cells, a small quantity of which is obtained from Celltech Ltd. Clones expressing the highest levels are subjected to successive rounds of amplification of the newly introduced DNA sequences in increasing concentrations of methotrexate. Stable CHO cell lines are thus generated which secrete at least 1 microgram/milliliter of mutant HIV- l gpl20.

11. Purification of HIV-l gp!20 proteins.

A one-step immunoaffinity procedure is used to purify the recombinant gpl20 molecules described. Briefly, culture supernatant is collected and clarified by centrifugation. An immunoaffinity column consisting of a matrix coupled to a sheep polyclonal anti-gpl20 IgG (D7234, Aalto Bioreagents) directed against the highly conserved C-terminal end

(APTKAKRRWQREKR) of gpl20 is used to specifically adsorb gpl20 from the cell culture media. This antisera recognizes native gpl20, the V3 loop deletion mutants, and the CD4^W mutants since the C-terminal ends of these molecules remain unaltered. The bound gpl20 is then eluted with 2M MgCl₂, concentrated by Amicon filtration, and dialyzed into 10 mM HEPES, pH 7.0. The purity of the proteins is determined by SDS-PAGE and silver staining.

12. Characterization of recombinant HIV-l gp!20 proteins. The purified glycoproteins are subjected to extensive biochemical and immunologic characterization. The integrity of the proteins is monitored by SDS-PAGE and silver staining under reducing and non-reducing conditions. The glycoproteins are deglycosylated by treatment with the enzyme N-glycosidase F which cleaves N-linked oligo- saccharides, and are assayed by SDS-PAGE and silver staining to ^' monitor molecular weight shifts. The purified glycoproteins are also tested for reactivity with several well characterized anti-gpl20 monoclonal antibodies that recognize both linear and discontinuous epitopes. The binding affinity to sCD4 is estimated using an ELISA assay.

The purified proteins HIV-l gpl20LAi# gP^ -LAi-V^ > gP¹²0__Ar^v3^(~ ⁾-CD4⁽-\ gpl20j_R._PL, plSOj_R._PL-VS , and gpl20j_R._FL-V3⁽-⁾-CD4⁽-⁾, were tested for their ability to bind cell surface human CD4. DG44 #3 cells, a recombinant cell line designed to express human CD4 on the membrane surface, were grown in T flasks and trypsinized. 5 X 10⁵ cells/experiment were aliquoted into FACS buffer (PBS + 2% BSA and 0.1% NaN₃) , washed several times in the same buffer, and then incubated with 100 ul of a solution of purified gpl20 protein at 5ug/ml in FACS buffer at 37°C for 2 hr. The cells were washed in FACS buffer, and then incubated in 100 ul solution containing 5ug/ml sheep polyclonal IgG against the highly conserved C- terminus of gpl20 in FACS buffer at 37°C for 2 hr. The cells were washed in FACS buffer then incubated in 100 ul solution containing FITC-labeled rabbit anti-sheep IgG polyclonal antibody at 37°C for 2 hr. The cells were washed with FACS buffer and then resuspended in 500 ul FACS buffer. The cells were then analyzed on a Becton Dickinson FACScan according to the manufacturer's instructions. As a control for expression of CD4 on the DG44 #3 cells, FITC-labeled 0KT4A (Becton Dickinson) was used.

13. A protocol for inoculation of animals with the mutant HIV-l gp!20 envelope glycoproteins.

Alum is used as an adjuvant during the inoculation series. The inoculum is prepared by dissolving the mutant HIV-l gpl20 envelope glycoprotein antigen in physiologic saline at a final antigen concentration of 100 ug/ml. Preformed alum (aluminum hydroxide gel) is added to the solution to a final level of 500 ug/ml aluminum. The antigen is allowed to adsorb onto the alum gel for two hours at room temperature. Following adsorption, the gel with the antigen is washed twice with physiologic saline and resuspended in the saline to a protein concentration of 100 ug/ml.

Monkeys and/or Guinea Pigs are individually inoculated with four 100 ug doses of the mutant HIV-l gpl20 envelope glycoprotein antigen adsorbed onto alum. Each dose is injected intramuscularly. The doses are delivered one or five months apart (week 0, 4, 8 and 28) . the animals are bled at intervals of two or four weeks. Serum samples are prepared from each bleed to assay for the development of specific antibodies as described in the subsequent sections.

14. Analysis of sera for anti-mutant HIV-l gpl20 envelope glycoprotein IgG antibodies.

Each serum sample is analyzed by ELISA. Polystyrene microtiter plates are coated with 0.5 ug per well of pure mutant HIV-l gpl20 envelope glycoprotein in phosphate- buffered physiological saline (PBS) at 4°C. Each well is then washed with PBS containing 0.5% T EEN-20 (PBS-TW) . Test serum, diluted serially in PBS-TW, is added to the mutant HIV-l gpl20 envelope glycoprotein-containing wells and allowed to react with the adsorbed mutant HIV-l .gpl20 envelope glycoprotein for one hour at 37°C. The wells are then washed extensively in PBS-TW. Each well then receives 0.1% p-nitrophenyl phosphate in 10% diethanolamine, pH 9.8, containing 0.5 mM MgCl₂.6H₂0. The ensuing reaction is allowed to proceed at room temperature for 30 minutes, at which time it is terminated by the addition of 3.0 N NaOH.

The greater the interaction of antibodies in the test serum with the mutant HIV-l gpl20 envelope glycoprotein, the greater is the amount of alkaline phosphatase bound onto the well. The phosphatase enzyme mediates the breakdown of p- nitrophenyl phosphate into a molecular substance which absorbs light at a wavelength of 405 nm. Hence, there exists a direct relationship between the absorbance at 405 nm of light at the end of the ELISA reaction and the amount of mutant HIV-l gpl20 envelope glycoprotein-bound antibody. All animals inoculated with mutant HIV-l gpl20 envelope glycoprotein whose serum reacts specifically with the mutant HIV-l gpl20 envelope glycoprotein in the ELISA have a positive antibody response against mutant HIV-l gpi20 envelope glycoprotein.

15. Analysis of sera for activity which specifically neutralizes HIV-l infectivity. Virus-neutralizing activity is determined with an assay based on the use of multiplicity curves in which the ratio of infectious virus surviving antibody treatment (V_n) is compared to infectious virus in uninhibited cultures (V„) at various dilutions of antisera. The neutralization titer of the sera is then interpolated as that sera dilution which yields one log reduction in infectious titer (i.e., V_n/V₀ = 0.1). Briefly, 4-fold dilutions of virus (laboratory- adapted and primary isolates) are prepared to yield infectious doses of 0.1 to 100 TCID₅₀ (Tissue Culture Infection Dose) in 20 ul. Serial 3-fold dilutions of sera are also prepared and 20 ul of each serum dilution are incubated with each dilution of virus in duplicate for 60 minutes at room temperature in a 96-well microtiter plate. 20 ul of AA5 cells (PHA stimulated PBMCs for primary HIV-l isolates) are then added to the serum/virus mixtures. Cells are cultured for 7 days by the addition of fresh medium every other day. On the seventh day, supernatant from each well is removed and tested for the presence of reverse transcriptase (RT) . Infection in each well is then scored as either positive or negative based on the RT counts, and the infectious dose of virus in each treatment group is calculated using the Reed and Muench (28) formula. The neutralization titers represent the reciprocal serum dilution required to reduced infectious dose of virus by one log. The above culture time is for the prototypic HIV-l^ isolate tested on the AA5 cell line. In the case of primary isolates, the termination date is usually 11-14 days. Culture conditions for PBMCs is not as demanding since doubling time is restricted. In the case of PBMCs, one day PHA stimulations are used at a final concentration of 1.5 X lOVml on day 0. Half that number of fresh PBMCs are then added again on days 4 and 8. This multiple addition of PBMCs is meant to amplify virus output upon successful infection so that the readout RT signal is strong. Again, the final readout titer for the primary isolate/PBMC is the reciprocal serum dilution which reduces infectious titer by one log. 16. Passive hyperimmune therapy.

Non-HIV-1-infected humans are immunized with the mutant HIV- 1 gpl20 envelope glycoprotein antigens according to a protocol similar to that described above in section 12. For passive hyperimmune therapy in HIV-l-infected individuals, blood plasma is taken from mutant HIV-l gpl20 envelope glycoprotein immunized, non-HIV-l-infected human donors whose plasma has high levels of neutralizing antibodies. The plasma is pooled from several donors, purified to remove nonimmunoglobulin proteins and is then sterilized to kill any other viruses or pathogens. The treated plasma is then injected into individuals infected with HIV-l, with repeated injections every week, every two weeks, or every month.

Results

Eukaryotic expression vectors designed to express high levels of HIV-l^ gpl20 and HIV-1_/R._FL gpl20 were constructed. The CMV MIE promoter/enhancer was used to drive, the transcription of a gene fusion consisting of the human tPA signal sequence fused to mature gpl20 (Figures 2 and 7) . The complete sequence of the transcription unit from the Hinc II site of the CMV promoter/enhancer to the Not I site just 3' from the stop codon in gpl20 is shown in figure 3. This vector was used to transfect C0SM5 cells in a transient assay. The transfected cells were labeled with ³⁵S-cysteine and the media immunoprecipitated with a CD4-immunoglobulin- Protein A-Sepharose complex. The precipitated products were analyzed using a reducing 10% SDS-PAGE gel and autoradiography (Figure 4) . A 120 kD band was detected when PPI4-tPA-gpl2θ_LAi was used to transfect COS cells (lane 3) . A band migrating with a slightly lower molecular mass was detected when PPI4-tPA-gpl20_R.p_L was used to transfect COS cells (lane 4) . No radiolabeled products were detected in the mock infected cells. Using a sheep polyclonal antibody directed against the highly conserved C-terminal end of HIV- 1 gpl20 in an ELISA assay, the level of expression of HIV-l gpl20 was determined to be 2350 ng/ l.

The PPI4-tPA-gpl20_IJU vector was then used to stably transfect the dhfr^" CHO cell line DXBll. Two days post- transfection, the cells were plated at low density in nucleoside-free medium. Eight days post-transfection, surviving clones were isolated and expanded. Individual primary transfectants were tested for gpl20 expression using the ELISA method described in the methods section. Several primary CHO transfectants expressed significant quantities

(10-120 ng/ml) of gpl20 (Figure 5) . Three of the highest expressing clones were then subjected to increasing concentrations of methotrexate in order to amplify, in tandem, the copy number of the dhfr and gpl20 genes. Cell lines were established that express high levels of gpl20 with rates of secretion greater than 1 mg/liter. These were then used to purify gpl20 to homogeneity.

Six CHO cell lines were established, using the procedures uc-. ^i -.JJCU -Lii .Lin. me ι_.i.-.u<__.-_> acu j-ύπa , UHCI L CΛ l css ul^u C C- S of the following proteins: HIV-l gpl20_LAi# gp^O^-VS⁰, gpl20_LA1-V3⁽-⁾-CD4⁽-⁾, gpl20j_R._FL, gpl20j_R._FL-V3^"), and gpl20j_R._FL-V3^w- CD4°. Metabolic labeling of these cells with ³⁵S-cysteine followed by immunoprecipitation with the human monoclonal antibody F105 and analyzed by SDS-PAGE and autoradiography showed the presence of the gpl20 proteins in the culture supernatant (Figure 14) . From these cell lines the gpl20 proteins were purified to homogeneity. Analysis by SDS-PAGE followed by silver-staining showed the purity of these proteins to be greater than 90% (Figure 15) .

It was shown by FACScan analysis that the two CD4 binding mutants HIV-lgpl20_LAI-V3⁽-⁾-CD4⁽-⁾and HIV-l gpl20_JR._FL-V3⁽-⁾-CD4⁽- had no appreciable binding to recombinant cell lines designed to express high levels of human CD4 on their membrane surface (Figure 16, panel 4 and data not shown, respectively) .

Discussion

The advantage of using the mutant HIV-l gpl20 envelope glycoproteins as immunogens is that these proteins will not elicit an immune response against the V3 loop, a highly immunodominant epitope on gpl20. This is significant because the V3 loop may skew the humoral immune response away from discontinuous epitopes in the CD4-binding site. Mutant HIV-l gpl20 envelope glycoproteins having partial and total V3 loop deletions have been made (30) . Deletion of the V3 loop therefore exposes the CD4-binding site to the immune system, allowing the immune system to mount a response against this critical region (18) . Another advantage of using the mutant HIV-l gpl20 envelope glycoprotein as an immunogen is that it has significantly reduced affinity for cell surface CD4. An efficient humoral immune response depends on the binding of antigen to B cell surface immunoglobulin. The presence of the high-affinity CD4 receptor on large numbers of cells in the body may significantly diminish the ability of native gpl20 to induce an effective humoral immune response. The rationale of mutating gpl20 at the CD4 binding site is to redirect the mutant HIV-l gpl20 envelope glycoprotein away from cell surface CD4 toward immunoglobulin-bearing B cells, thereby allowing the immune system to mount a response against, inter alia, the CD4-binding site.

References

1. Klatzmann, D.R., et. al. (1990) Immunodeficiency Reviews 2, 43-66.

2. Lasky, L.A., et. al. (1987) Cell 50, 975-985.

3. Maddon, P.J., et. al. (1986) Cell 47, 333-348.

4. Haddon, P.J., et. ai. (1966) Ceil 54, 655-674.

5. Maddon, P.J., et. al. (1985) Cell 42, 93-104.

6. Maddon, P.J., et. al. (1987) Proc. Natl. Acad. Sci. U.S.A. 84, 9155-9159.

7. Richardson, N.E., et. al. (1988) Proc. Natl. Acad. Sci. U.S.A. 85, 6102-6106.

8. Chao, B.H., et. al. (1989) J. Biol. Chem. 264, 5812- 5817.

9. Arthos, J., et. al. (1989) Cell 57, 469-481.

10. Wang, J. , et. al. (1990) Nature 348, 411-418.

11. Ryu, S.-E., et. al. (1990) Nature 348, 419-426.

12. Leonard, C.K., et. al. (1990) J. Biol. Chem. 265, 10373-10382.

13. Earl, P.L., et. al. (1990) Proc. Natl. Acad. Sci. U.S.A. 87, 648-652.

14. Helseth, E., et. al. (1991) J. Virol. 65, 2119-2123. 15. Bolognesi, D.P. (1990) TIBTech 8, 40-45.

16. Olshevsky, U. , et. al. (1990) J. Virol. 64, 5701-5707.

17. Steimer, K.S., et. al. (1991) AIDS 5, S135-143.

18. Wyatt, R., et. al. (1992) J. Virol. 66, 6997-7004.

19. Zolla-Pazner, S., et. al. (1992) Sem. in Virology 3, 203-211.

20. Steimer, K.S., et. al. (1991) Science 254, 105-108.

21. Pollard, S.R., et. al. (1992) EMBO J. 11, 585-591.

22. Okayama, H. (1983) Mol. Cell. Biol. 3, 280-289.

23. Maniatis, T. , et. al. (1990) Molecular Cloning, Vol. 1- 3.

24. Thomsen, D.R., et. al. (1984) Proc. Natl. Acad. Sci. U.S.A. 81, 659-663.

25. Pennica, D., et. al. (1983) Nature 301, 214-221.

26. Wain-Hobson, S., et. al. (1985) Cell 40, 9-17.

27. Koyanagi, Y. (1987) Science 236, 819-822.

28. Reed, L.J. (1938) Am. J. Hyg., 27, 493-497.

29. Co n, E.J. et al., (1944) J. Clin. Invest. 23, 417-432.

30. Shiow-Her, C, et al. (1992) J. of Cellular Biochem. , Supplement 16E, Abstrtact Q105. SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT: Progenies Pharmaceuticals, Inc.

(ii) TITLE OF INVENTION: HIV-1 VACCINES, ANTIBOOY COMPOSITIONS RELATED

THERETO, AND THERAPEUTIC AND PROPHYLACTIC USES THEREOF

(iii) NUMBER OF SEQUENCES: 29

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: Cooper & Dunham

(B) STREET: 30 Rockefeller Plaza

(C) CITY: New York CD) STATE: New York

(E) COUNTRY: USA

(F) ZIP: 10112

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk (B. COMPUTER: IBM PC compatible

(C) OPERATING SYSTEM: PC-DOS/MS-DOS

(D) SOFTWARE: PatentIn Release #1.24

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER:

(B) FILING DATE:

(C) CLASSIFICATION:

(vii) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER: US 08/037,816

(B) FILING DATE: 26-MAR-1993

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: White, John P.

(B) REGISTRATION NUMBER: 28,678

(C) REFERENCE/DOCKET NUMBER: 41190-A-PCT/JPW/AJM

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: (212) 977-9550

(B) TELEFAX: (212) 664-0525

(C) TELEX: 422523 COOPUI

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 45 amino acids

(B) TYPE: amino acid

(C) STRANOEONESS: single

(D) TOPOLOGY: linear

( ) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

Xaa Xaa Xaa Cys Xaa He Xaa Xaa Xaa Xaa Xaa Xaa Trp Xaa Xaa Xaa 1 5 10 15

Xaa Xaa Ala Xaa Tyr Xaa Xaa Pro Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 30

Ser Xaa Xaa Thr Gly Xaa Xaa Xaa Xaa Arg Xaa Gly Xaa 35 40 45

(2) INFORMATION FOR SEQ ID N0:2:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 45 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Thr Leu Pro Cys Arg He Lys Gin Phe He Asn Met Trp Gin Glu Val 1 5 10 15

Gly Lys Ala Met Tyr Ala Pro Pro He Ser Gly Gin He Arg Cys Ser 20 25 30

Ser Asn He Thr Gly Leu Leu Leu Thr Arg Asp Gly Gly 35 40 45

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 45 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

Thr Leu Pro Cys Arg He Lys Gin He He Asn Met Trp Gin Glu Val 1 5 10 15

Gly Lys Ala Met Tyr Ala Pro Pro He Arg Gly Gin He Arg Cys Ser 20 25 30

Ser Asn He Thr Gly Leu Leu Leu Thr Arg Asp Gly Gly 35 40 45

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 45 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genoaic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4: GATCCTGCAG TCACCGTCCT TGACACGATG GATGCAATGA AGAGA 45

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 36 base pairs

(B) TYPE: nucleic acid (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5: AAGTCTTCTC CTCGGTCTTG TCTTTTTAAC ACCCAG 36 (2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTE ISTICS:

(A) LENGTH: 36 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6: TTCAGAAGAG GAGCCAGAAC AGAAAAATTG TGGGTC 36 (2) INFORMATION FOR SEQ ID N0:7:

(i) SE^QUENCE CHARACTERISTICS:

(A) LENGTH: 39 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7: GGAAAAAAGC GGCCGCTCAT TTTTCTCTCT GCACCACTC 39 (2) INFORMATION FOR SEQ ID NO:8:

(i) SE^QUENCE CHARACTERISTICS:

(A) LENGTH: 33 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (gerwaie)

(Xi) SEQUENCE DESCRIPTION: SEQ ID NO:8: GATCGGCGCC AGAGTAGAAA AGTTGTGGGT CAC 33 (2) INFORMATION FOR SEQ ID N0:9:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 49 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID N0:9: CTGTAGAAAT TAATTGTACA GGTGCTGGAC ATTGTAACAT TAGTAGAGC 49 (2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 29 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10: CTCGAGCATG CATTCGAAGC TCGCTGATC 29 (2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 29 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11: CAATTTATAA ACATGGTGCA GGAAGTAGG 29 (2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 29 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12: CAAATTATAA ACATGGTGCA GGAAGTAGG 29 (2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 3125 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 1555..3115 (D) OTHER INFORMATION: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

TTGACATTGA TTATTGACTA GTTATTAATA GTAATCAATT ACGGGGTCAT TAGTTCATAG 60

CCCATATATG GAGTTCCGCG TTACATAACT TACGGTAAAT GGCCCGCCTG GCTGACCGCC 120

CAACGACCCC CGCCCATTGA CGTCAATAAT GACGTATGTT CCCATAGTAA CGCCAATAGG 180

GACTTTCCAT TGACGTCAAT GGGTGGACTA TTTACGGTAA ACTGCCCACT TGGCAGTACA 240

TCAAGTGTAT CATATGCCAA GTACGCCCCC TATTGACGTC AATGACGGTA AATGGCCCGC 300

CTGGCATTAT GCCCAGTACA TGACCTTATG GGACTTTCCT ACTTGGCAGT ACATCTACGT 360

ATTAGTCATC GCTATTACCA TGGTGATGCG GTTTTGGCAG TACATCAATG GGCGTGGATA 420

GCGGTTTGAC TCACGGGGAT TTCCAAGTCT CCACCCCATT GACGTCAATG GGAGTTTGTT 480

TTGGCACCAA AATCAACGGG ACTTTCCAAA ATGTCGTAAC AACTCCGCCC CATTGACGCA 540

AATGGGCGGT AGGCGTGTAC GGTGGGAGGT CTATATAAGC AGAGCTCGTT TAGTGAACCG 600

TCAGATCGCC TGGAGACGCC ATCCACGCTG TTTTGACCTC CATAGAAGAC ACCGGGACCG 660

ATCCAGCCTC CGCGGCCGGG AACGGTGCAT TGGAACGCGG ATTCCCCGTG CCAAGAGTGA 720

CGTAAGTACC GCCTATAGAC TCTATAGGCA CACCCCTTTG GCTCTTATGC ATGCTATACT 780

GTTTTTGGCT TGGGCCAACA CCCCGTCCTA GATAGGTGAT GGTATAGCTT AGCCTATAGG 840

TGTGGGTTAT TGACCATTAT TGACCACTCC CCTATTGGTG ACGATACTTT CCATTACTAA 900

TCCATAACAT GGCCGCTCTT TGCCACAACT ATCTCTATTG GCTATATGCC AATACTCTGT 960

CCTTCAGAGA CTGACACGGA CTCTGTATTT TTACAGGATG GGGTCCCATT TATTATTTAC 1020

AAATTCACAT ATACAACAAC GCCGTCCCCC GTGCCCGCAG TTTTTATTAA CATGCGGGAT 1080

CTCCACGCGA ATCTCGGGTA CGTGTTCCGG ACATGGGCTC TTCTCCGGTA GCGGCGGAGC 1140

TCCACATCCG AGCCTGTCCC ATGCCCATGC CTCCAGCGGC TCATGGTCGC TCGGCAGCTC 1200

CTTGCTCCTA ACAGTGGAGG CCAGACTTAG GCACAGGACA ATGCCCACCA CCACCAGTGT 1260

GCCGCACAAG GCCGTGGCGG TAGGGTATGT GTCTGAAAAT GAGCTCGGAG ATTGGGCTCG 1320

CACCGCTGAC GCAGATGGAA GACTTAAGGC AGCGGCAGAA GAAGATGCAG GCAGCTGAGT 1380

TGTTGTATTC TGTAGAGTTG GAGGTAACTC CCGTTGCGGT GCTGTTAACG GTGGAGGGCA 1440

GTGTAGTCTG AGCAGTACTC GTTGCTGCCG CGCGCGCCAC CAGACATAAT AGCTGACAGA 1500

CTAACAGACT GTTCCTTTCC ATGGGTCTTT TCTGCAGTCA CCGTCCTTGA CACG ATG 1557

Met 1

GAT GCA ATG AAG AGA GGG CTC TGC TGT GTG CTG CTG CTG TGT GGA GCA 1605 Asp Ala Met Lys Arg Gly Leu Cys Cys Val Leu Leu Leu Cys Gly Ala 5 10 15

GTC TTC GTT TCG CCC AGC CAG GAA ATC CAT GCC CGA TTC AGA AGA GGC 1653 Val Phe Val Ser Pro Ser Gin Glu He His Ala Arg Phe Arg Arg Gly 20 25 30

GCC AGA ACA GAA AAA TTG TGG GTC ACA GTC TAT TAT GGG GTA CCT GTG 1701 Ala Arg Thr Glu Lys Leu Trp Val Thr Val Tyr Tyr Gly Val Pro Val 35 40 45

TGG AAG GAA GCA ACC ACC ACT CTA TTT TGT GCA TCA GAT GCT AAA GCA 1749 Trp Lys Glu Ala Thr Thr Thr Leu Phe Cys Ala Ser Asp Ala Lys Ala 50 55 60 65

TAT GAT ACA GAG GTA CAT AAT GTT TGG GCC ACA CAT GCC TGT GTA CCC 1797

Tyr Asp Thr Glu Val His Asn Val Trp Ala Thr His Ala Cys Val Pro 70 75 80

ACA GAC CCC AAC CCA CAA GAA GTA GTA TTG GTA AAT GTG ACA GAA AAT 1845

Thr Asp Pro Asn Pro Gin Glu Val Val Leu Val Asn Vat Thr Glu Asn 85 90 95

TTT AAC ATG TGG AAA AAT GAC ATG GTA GAA CAG ATG CAT GAG GAT ATA 1893

Phe Asn Met Trp Lys Asn Asp Met Val Glu Gin Met His Glu Asp He 100 105 110

ATC AGT TTA TGG GAT CAA AGC CTA AAG CCA TGT GTA AAA TTA ACC CCA 1941 lie Ser Leu Trp Asp Gin Ser Leu Lys Pro Cys Val Lys Leu Thr Pro 115 120 125

CTC TGT GTT AGT TTA AAG TGC ACT GAT TTG GGG AAT GCT ACT AAT ACC 1989

Leu Cys Val Ser Leu Lys Cys Thr Asp Leu Gly Asn Ala Thr Asn Thr 130 135 140 145

AAT AGT AGT AAT ACC AAT AGT AGT AGC GGG GAA ATG ATG ATG GAG AAA 2037

Asn Ser Ser Asn Thr Asn Ser Ser Ser Gly Glu Met Met Met Glu Lys 150 155 160

GGA GAG ATA AAA AAC TGC TCT TTC AAT ATC AGC ACA AGC ATA AGA GGT 2085

Gly Glu He Lys Asn Cys Ser Phe Asn He Ser Thr Ser He Arg Gly

165 170 175

AAG GTG CAG AAA GAA TAT GCA TTT TTT TAT AAA CTT GAT ATA ATA CCA 2133

Lys Val Gin Lys Glu Tyr Ala Phe Phe Tyr Lys Leu Asp He He Pro 180 185 190

ATA GAT AAT GAT ACT ACC AGC TAT ACG TTG ACA AGT TGT AAC ACC TCA 2181

I le Asp Asn Asp Thr Thr Ser Tyr Thr Leu Thr Ser Cys Asn Thr Ser 195 200 205

GTC ATT ACA CAG GCC TGT CCA AAG GTA TCC TTT GAG CCA ATT CCC ATA 2229

Val He Thr Gin Ala Cys Pro Lys Val Ser Phe Glu Pro He Pro He 210 215 220 225

CAT TAT TGT GCC CCG GCT GGT TTT GCG ATT CTA AAA TGT AAT AAT AAG 2277

His Tyr Cys Ala Pro Ala Gly Phe Ala He Leu Lys Cys Asn Asn Lys 230 235 240

ACG TTC AAT GGA ACA GGA CCA TGT ACA AAT GTC AGC ACA GTA CAA TGT 2325

Thr Phe Asn Gly Thr Gly Pro Cys Thr Asn Val Ser Thr Val Gin Cys

245 250 255

ACA CAT GGA ATT AGG CCA GTA GTA TCA ACT CAA CTG CTG TTG AAT GGC 2373

Thr His Gly He Arg Pro Val Val Ser Thr Gin Leu Leu Leu Asn Gly 260 265 270

AGT CTA GCA GAA GAA GAG GTA GTA ATT AGA TCT GCC AAT TTC ACA GAC 2421

Ser Leu Ala Glu Glu Glu Val Val He Arg Ser Ala Asn Phe Thr Asp 275 280 285

AAT GCT AAA ACC ATA ATA GTA CAG CTG AAC CAA TCT GTA GAA ATT AAT 2469

Asn Ala Lys Thr He He Val Gin Leu Asn Gin Ser Val Glu He Asn 290 295 300 305

TGT ACA AGA CCC AAC AAC AAT ACA AGA AAA AGT ATC CGT ATC CAG AGG 2517

Cys Thr Arg Pro Asn Asn Asn Thr Arg Lys Ser He Arg He Gin Arg 310 315 320

GGA CCA GGG AGA GCA TTT GTT ACA ATA GGA AAA ATA GGA AAT ATG AGA 2565

Gly Pro Gly Arg Ala Phe Val Thr He Gly Lys He Gly Asn Met Arg 325 330 335

CAA GCA CAT ^TGT AAC ATT AGT AGA GCA AAA TGG AAT GCC ACT TTA AAA 2613 Gin Ala His Cys Asn lie Ser Arg Ala Lys Trp Asn Ala Thr Leu Lys 340 345 350

CAG ATA GCT AGC AAA TTA AGA GAA CAA TTT GGA AAT AAT AAA ACA ATA 2661 Gin lie Ala Ser Lys Leu Arg Glu Gin Phe Gly Asn Asn Lys Thr lie 355 360 365

ATC TTT AAG CAA TCC TCA GGA GGG GAC CCA GAA ATT GTA ACG CAC AGT 2709 He Phe Lys Gin Ser Ser Gly Gly Asp Pro Glu He Val Thr His Ser 370 375 380 385

TTT AAT TGT GGA GGG GAA TTT TTC TAC TGT AAT TCA ACA CAA CTG TTT 2757 Phe Asn Cys Gly Gly Glu Phe Phe Tyr Cys Asn Ser Thr Gin Leu Phe 390 395 400

AAT AGT ACT TGG TTT AAT AGT ACT TGG AGT ACT GAA GGG TCA AAT AAC 2805 Asn Ser Thr Trp Phe Asn Ser Thr Trp Ser Thr Glu Gly Ser Asn Asn 405 410 415

ACT GAA GGA AGT GAC ACA ATC ACA CTC CCA TGC AGA ATA AAA CAA TTT 2853 Thr Glu Gly Ser Asp Thr He Thr Leu Pro Cys Arg He Lys Gin Phe 420 425 430

ATA AAC ATG TGG CAG GAA GTA GGA AAA GCA ATG TAT GCC CCT CCC ATC 2901 He Asn Met Trp Gin Glu Val Gly Lys Ala Met Tyr Ala Pro Pro He 435 440 445

AGC GGA CAA ATT AGA TGT TCA TCA AAT ATT ACA GGG CTG CTA TTA ACA 2949 Ser Gly Gin He Arg Cys Ser Ser Asn He Thr Gly Leu Leu Leu Thr 450 455 460 465

AGA GAT GGT GGT AAT AAC AAC AAT GGG TCC GAG ATC TTC AGA CCT GGA 2997 Arg Asp Gly Gly Asn Asn Asn Asn Gly Ser Glu He Phe Arg Pro Gly 470 475 480

GGA GGA GAT ATG AGG GAC AAT TGG AGA AGT GAA TTA TAT AAA TAT AAA 3045 Gly Gly Asp Met Arg Asp Asn Trp Arg Ser Glu Leu Tyr Lys Tyr Lys 485 490 495

GTA GTA AAA ATT GAA CCA TTA GGA GTA GCA CCC ACC AAG GCA AAG AGA 3093 Val Val Lys He Glu Pro Leu Gly Val Ala Pro Thr Lys Ala Lys Arg 500 505 510

AGA GTG GTG CAG AGA GAA AAA T GAGCGGCCGC 3125

Arg Val Val Gin Arg Glu Lys 515 520

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 520 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

Met Asp Ala Met Lys Arg Gly Leu Cys Cys Val Leu Leu Leu Cys Gly 1 5 10 15

Ala Val Phe Val Ser Pro Ser Gin Glu He His Ala Arg Phe Arg Arg 20 25 30

Gly Ala Arg Thr Glu Lys Leu Trp Val Thr Val Tyr Tyr Gly Val Pro 35 40 45

Val Tro Lys Glu Ala Thr Thr Thr Leu Phe Cys Ala Ser Asp Ala Lys 50 55 60

Ala Tyr Asp Thr Glu Val His Asn Val Trp Ala Thr His Ala Cys Val 65 70 75 80

Pro Thr Asp Pro Asn Pro Gin Glu Val Val Leu Val Asn Val Thr Glu 85 90 95

Asn Phe Asn Met Trp Lys Asn Asp Met Val Glu Gin Met His Glu Asp 100 105 110

He He Ser Leu Trp Asp Gin Ser Leu Lys Pro Cys Val Lys Leu Thr 115 120 125

Pro Leu Cys Val Ser Leu Lys Cys Thr Asp Leu Gly Asn Ala Thr Asn 130 135 140

Thr Asn Ser Ser Asn Thr Asn Ser Ser Ser Gly Glu Met Met Met Glu 145 150 155 160

Lys Gly Glu He Lys Asn Cys Ser Phe Asn He Ser Thr Ser He Arg 165 170 175

Gly Lys Val Gin Lys Glu Tyr Ala Phe Phe Tyr Lys Leu Asp He He 180 185 190

Pro He Asp Asn Asp Thr Thr Ser Tyr Thr Leu Thr Ser Cys Asn Thr 195 200 205

Ser Val He Thr Gin Ala Cys Pro Lys Val Ser Phe Glu Pro He Pro 210 215 220

He His Tyr Cys Ala Pro Ala Gly Phe Ala He Leu Lys Cys Asn Asn 225 230 235 240

Lys Thr Phe Asn Gly Thr Gly Pro Cys Thr Asn Val Ser Thr Val Gin 245 250 255

Cys Thr His Gly He Arg Pro Val Val Ser Thr Gin Leu Leu Leu Asn 260 265 270

Gly Ser Leu Ala Glu Glu Glu Val Val He Arg Ser Ala Asn Phe Thr 275 280 285

Asp Asn Ala Lys Thr He He Val Gin Leu Asn Gin Ser Val Glu He 290 295 300

Asn Cys Thr Arg Pro Asn Asn Asn Thr Arg Lys Ser He Arg He Gin 305 310 315 320

Arg Gly Pro Gly Arg Ala Phe Val Thr He Gly Lys He Gly Asn Met 325 330 335

Arg Gin Ala His Cys Asn He Ser Arg Ala Lys Trp Asn Ala Thr Leu 340 345 350

Lys Gin He Ala Ser Lys Leu Arg Glu Gin Phe Gly Asn Asn Lys Thr 355 360 365

He He Phe Lys Gin Ser Ser Gly Gly Asp Pro Glu He Val Thr His 370 375 380

Ser Phe Asn Cys Gly Gly Glu Phe Phe Tyr Cys Asn Ser Thr Gin Leu 385 390 395 400

Phe Asn Ser Thr Trp Phe Asn Ser Thr Trp Ser Thr Glu Gly Ser Asn 405 410 415

Asn Thr Glu Gly Ser Asp Thr He Thr Leu Pro Cys Arg He Lys Gin 420 425 430

Phe He Asn Met Trp Gin Glu Val Gly Lys Ala Met Tyr Ala Pro Pro 435 4 0 445 lie Ser Gly Gin He Arg Cys Ser Ser Asn He Thr Gly Leu Leu Leu 450 455 460

Thr Arg Asp Gly Gly Asn Asn Asn Asn Gly Ser Glu He Phe Arg Pro 465 470 475 480

Gly Gly Gly Asp Met Arg Asp Asn Trp Arg Ser Glu Leu Tyr Lys Tyr 485 490 495

Lys Val Val Lys He Glu Pro Leu Gly Val Ala Pro Thr Lys Ala Lys 500 505 510

Arg Arg Val Val Gin Arg Glu Lys 515 520

(2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1532 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 1..1522 (D) OTHER INFORMATION:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

ATG GAT GCA ATG AAG AGA GGG CTC TGC TGT GTG CTG CTG CTG TGT GGA 48 Met Asp Ala Met Lys Arg Gly Leu Cys Cys Val Leu Leu Leu Cys Gly 1 5 10 15

GCA GTC TTC GTT TCG CCC AGC CAG GAA ATC CAT GCC CGA TTC AGA AGA 96 Ala Val Phe Val Ser Pro Ser Gin Glu He His Ala Arg Phe Arg Arg 20 25 30

GGC GGC AGA GTA GAA AAG TTG TGG GTC ACA GTC TAT TAT GGG GTA CCT 144 Gly Gly Arg Val Glu Lys Leu Trp Val Thr Val Tyr Tyr Gly Val Pro 35 40 45

GTG TGG AAA GAA GCA ACC ACC ACT CTA TTT TGT GCA TCA GAT^' GCT AAA 192 Val Trp Lys Glu Ala Thr Thr Thr Leu Phe Cys Ala Ser Asp Ala Lys 50 55 60

GCA TAT GAT ACA GAG GTA CAT AAT GTT TGG GCC ACA CAT GCC TGT GTA 240 Ala Tyr Asp Thr Glu Val His Asn Val Trp Ala Thr His Ala Cys Val 65 70 75 80

CCC ACA GAC CCC AAC CCA CAA GAA GTA GTA TTG GAA AAT GTA ACA GAA 288 Pro Thr Asp Pro Asn Pro Gin Glu Val Val Leu Glu Asn Val Thr Glu 85 90 95

CAT TTT AAC ATG TGG AAA AAT AAC ATG GTA GAA CAG ATG CAG GAG GAT 336 His Phe Asn Met Trp Lys Asn Asn Met Val Glu Gin Met Gin Glu Asp 100 105 110 ATA ATC AGT TTA TGG GAT CAA AGC CTA AAG CCA TGT GTA AAA TTA ACC 384 lie He Ser Leu Trp Asp Gin Ser Leu Lys Pro Cys Val Lys Leu Thr 115 120 125

CCA CTC TGT GTT ACT TTA AAT TGC AAG GAT GTG AAT GCT ACT AAT ACC 432 Pro Leu Cys Val Thr Leu Asn Cys Lys Asp Val Asn Ala Thr Asn Thr 130 135 140

ACT AAT GAT AGC GAG GGA ACG ATG GAG AGA GGA GAA ATA AAA AAC TGC 480 Thr Asn Asp Ser Glu Gly Thr Met Glu Arg Gly Glu He Lys Asn Cys 145 150 155 160

TCT TTC AAT ATC ACC ACA AGC ATA AGA GAT GAG GTG CAG AAA GAA TAT 528 Ser Phe Asn He Thr Thr Ser He Arg Asp Glu Val Gin Lys Glu Tyr 165 170 175

GCT CTT TTT TAT AAA CTT GAT GTA GTA CCA ATA GAT AAT AAT AAT ACC 576 Ala Leu Phe Tyr Lys Leu Asp Val Val Pro He Asp Asn Asn Asn Thr 180 185 190

AGC TAT AGG TTG ATA AGT TGT GAC ACC TCA GTC ATT ACA CAG GCC TGT 624 Ser Tyr Arg Leu He Ser Cys Asp Thr Ser Val He Thr Gin Ala Cys 195 200 205

CCA AAG ATA TCC TTT GAG CCA ATT CCC ATA CAT TAT TGT GCC CCG GCT 672 Pro Lys He Ser Phe Glu Pro He Pro He His Tyr Cys Ala Pro Ala 210 215 220

GGT TTT GCG ATT CTA AAG TGT AAT GAT AAG ACG TTC AAT GGA AAA GGA 720 Gly Phe Ala He Leu Lys Cys Asn Asp Lys Thr Phe Asn Gly Lys Gly 225 230 235 240

CCA TGT AAA AAT GTC AGC ACA GTA CAA TGT ACA CAT GGA ATT AGG CCA 768 Pro Cys Lys Asn Val Ser Thr Val Gin Cys Thr His Gly He Arg Pro 245 250 255

GTA GTA TCA ACT CAA CTG CTG CTA AAT GGC AGT CTA GCA GAA GAA GAG 816 Val Val Ser Thr Gin Leu Leu Leu Asn Gly Ser Leu Ala Glu Glu Glu 260 265 270

GTA GTA ATT AGA TCT GAC AAT TTC ACG AAC AAT GCT AAA ACC ATA ATA 864 Val Val He Arg Ser Asp Asn Phe Thr Asn Asn Ala Lys Thr He He 275 280 285

GTA CAG CTG AAA GAA TCT GTA GAA ATT AAT TGT ACA AGA CCC AAC AAC 912 Val Gin Leu Lys Glu Ser Val Glu He Asn Cys Thr Arg Pro Asn Asn 290 295 300

AAT ACA AGA AAA AGT ATA CAT ATA GGA CCA GGG AGA GCA TTT TAT ACT 960 Asn Thr Arg Lys Ser He His He Gly Pro Gly Arg Ala Phe Tyr Thr 305 310 315 320

ACA GGA GAA ATA ATA GGA GAT ATA AGA CAA GCA CAT TGT AAC ATT AGT 1008 Thr Gly Glu He He Gly Asp He Arg Gin Ala His Cys Asn He Ser 325 330 335

AGA GCA AAA TGG AAT GAC ACT TTA AAA CAG ATA GTT ATA AAA TTA AGA 1056 Arg Ala Lys Trp Asn Asp Thr Leu Lys Gin He Val He Lys Leu Arg 340 345 350

GAA CAA TTT GAG AAT AAA ACA ATA GTC TTT AAT CAC TCC TCA GGA GGG 1104 Glu Gin Phe Glu Asn Lys Thr He Val Phe Asn His Ser Ser Gly Gly 355 360 365

GAC CCA GAA ATT GTA ATG CAC AGT TTT AAT TGT GGA GGA GAA TTT TTC 1152 Asp Pro Glu He Val Met His Ser Phe Asn Cys Gly Gly Glu Phe Phe 370 375 380

TAC TGT AAT TCA ACA CAA CTG TTT AAT AGT ACT TGG AAT AAT AAT ACT 1200 Tyr Cys Asn Ser Thr Gin Leu Phe Asn Ser Thr Trp Asn Asn Asn Thr 385 390 395 400

GAA GGG TCA AAT AAC ACT GAA GGA AAT ACT ATC ACA CTC CCA TGC AGA 1248 Glu Gly Ser Asn Asn Thr Glu Gly Asn Thr He Thr Leu Pro Cys Arg 405 410 415

ATA AAA CAA ATT ATA AAC ATG TGG CAG GAA GTA GGA AAA GCA ATG TAT 1296

He Lys Gin He He Asn Met Trp Gin Glu Val Gly Lys Ala Met Tyr :

420 425 430

GCC CCT CCC ATC AGA GGA CAA ATT AGA TGT TCA TCA AAT ATT ACA GGG 1344 Ala Pro Pro He Arg Gly Gin He Arg Cys Ser Ser Asn He Thr Gly 435 440 445

CTG CTA TTA ACA AGA GAT GGT GGT ATT AAT GAG AAT GGG ACC GAG ATC 1392 Leu Leu Leu Thr Arg Asp Gly Gly He Asn Glu Asn Gly Thr Glu He 450 455 460

TTC AGA CCT GGA GGA GGA GAT ATG AGG GAC AAT TGG AGA AGT GAA TTA 1440 Phe Arg Pro Gly Gly Gly Asp Met Arg Asp Asn Trp Arg Ser Glu Leu 465 470 475 480

TAT AAA TAT AAA GTA GTA AAA ATT GAA CCA TTA GGA GTA GCA CCC ACC 1488 Tyr Lys Tyr Lys Val Val Lys He Glu Pro Leu Gly Val Ala Pro Thr 485 490 495

AAG GCA AAG AGA AGA GTG GTG CAA AGA GAA AAA T GAGCGGCCGC 1532

Lys Ala Lys Arg Arg Val Val Gin Arg Glu Lys 500 505

(2) INFORMATION FOR SEQ ID NO:16:

(i) SE^QUENCE CHARACTERISTICS:

(A) LENGTH: 507 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SE^QUENCE DESCRIPTION: SEQ ID N0:16:

Met Asp Ala Met Lys Arg Gly Leu Cys Cys Val Leu Leu Leu Cys Gly 1 5 10 15

Ala Val Phe Val Ser Pro Ser Gin Glu He His Ala Arg Phe Arg Arg 20 25 30

Gly Gly Arg Val Glu Lys Leu Trp Val Thr Val Tyr Tyr Gly Val Pro 35 40 45

Val Trp Lys Glu Ala Thr Thr Thr Leu Phe Cys Ala Ser Asp Ala Lys 50 55 60

Ala Tyr Asp Thr Glu Val His Asn Val Trp Ala Thr His Ala Cys Val 65 70 75 80

Pro Thr Asp Pro Asn Pro Gin Glu Val Val Leu Glu Asn Val Thr Glu 85 90 95

His Phe Asn Met Trp Lys Asn Asn Met Val Glu Gin Met Gin Glu Asp 100 105 110

He He Ser Leu Trp Asp Gin Ser Leu Lys Pro Cys Val Lys Leu Thr 115 120 125

Pro Leu Cys Val Thr Leu Asn Cys Lys Asp Val Asn Ala Thr Asn Thr 130 135 140 Thr Asn Asp Ser Glu Gly Thr Met Glu Arg Gly Glu He Lys Asn Cys 145 150 155 160

Ser Phe Asn He Thr Thr Ser He Arg Asp Glu Val Gin Lys Glu Tyr 165 170 175

Ala Leu Phe Tyr Lys Leu Asp Val Val Pro He Asp Asn Asn Asn Thr 180 185 190

Ser Tyr Arg Leu He Ser Cys Asp Thr Ser Val He Thr Gin Ala Cys 195 200 205

Pro Lys He Ser Phe Glu Pro He Pro He His Tyr Cys Ala Pro Ala 210 215 220

Gly Phe Ala He Leu Lys Cys Asn Asp Lys Thr Phe Asn Gly Lys Gly 225 230 235 240

Pro Cys Lys Asn Val Ser Thr Val Gin Cys Thr His Gly He Arg Pro 245 250 255

Val Val Ser Thr Gin Leu Leu Leu Asn Gly Ser Leu Ala Glu Glu Glu 260 265 270

Val Val He Arg Ser Asp Asn Phe Thr Asn Asn Ala Lys Thr He He 275 280 285

Val Gin Leu Lys Glu Ser Val Glu He Asn Cys Thr Arg Pro Asn Asn 290 295 300

Asn Thr Arg Lys Ser He His He Gly Pro Gly Arg Ala Phe Tyr Thr 305 310 315 320

Thr Gly Glu He He Gly Asp He Arg Gin Ala His Cys Asn He Ser 325 330 335

Arg Ala Lys Trp Asn Asp Thr Leu Lys Gin He Val He Lys Leu Arg 340 345 350

Glu Gin Phe Glu Asn Lys Thr He Val Phe Asn His Ser Ser Gly Gly 355 360 365

Asp Pro Glu He Val Met His Ser Phe Asn Cys Gly Gly Glu Phe Phe 370 375 380

Tyr Cys Asn Ser Thr Gin Leu Phe Asn Ser Thr Trp Asn Asn Asn Thr 385 390 395 400

Glu Gly Ser Asn Asn Thr Glu Gly Asn Thr He Thr Leu Pro Cys Arg 405 410 415

He Lys Gin He He Asn Met Trp Gin Glu Val Gly Lys Ala Met Tyr 420 425 430

Ala Pro Pro He Arg Gly Gin He Arg Cys Ser Ser Asn He Thr Gly 435 440 445

Leu Leu Leu Thr Arg Asp Gly Gly He Asn^'Glu Asn Gly Thr Glu He 450 455 460

Phe Arg Pro Gly Gly Gly Asp Met Arg Asp Asn Trp Arg Ser Glu Leu 465 470 475 480

Tyr Lys Tyr Lys Val Val Lys He Glu Pro Leu Gly Val Ala Pro Thr 485 490 495

Lys Ala Lys Arg Arg Val Val Gin Arg Glu Lys 500 505 (2) INFORMATION FOR SEQ ID NO:17:

(l) SE^QUENCE CHARACTERISTICS:

(A) LENGTH: 1484 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

C MOLECULE TYPE: DNA (genomic)

(IX) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 1..1474 (D) OTHER INFORMATION:

(xi) SEQUENCE DESCRIPTION: SEQ ID N0:17:

GGC GCC AGA ACA GAA AAA TTG TGG GTC ACA GTC TAT TAT GGG GTA CCT 144 Gly Ala Arg Thr Glu Lys Leu Trp Val Thr Val Tyr Tyr Gly Val Pro 35 40 45

GTG TGG AAG GAA GCA ACC ACC ACT CTA TTT TGT GCA TCA GAT GCT AAA 192 Val Trp Lys Glu Ala Thr Thr Thr Leu Phe Cys Ala Ser Asp Ala Lys 50 55 60

CCC ACA GAC CCC AAC CCA CAA GAA GTA GTA TTG GTA AAT GTG ACA GAA 288 Pro Thr Asp Pro Asn Pro Gin Glu Val Val Leu Val Asn Val Thr Glu 85 90 95

AAT TTT AAC ATG TGG AAA AAT GAC ATG GTA GAA CAG ATG CAT GAG GAT 336 Asn Phe Asn Met Trp Lys Asn Asp Met Val Glu Gin Met His Glu Asp 100 105 110

ATA ATC AGT TTA TGG GAT CAA AGC CTA AAG CCA TGT GTA AAA TTA ACC 384 He He Ser Leu Trp Asp Gin Ser Leu Lys Pro Cys Val Lys Leu Thr 115 120 125

CCA CTC TGT GTT AGT TTA AAG TGC ACT GAT TTG GGG AAT GCT ACT AAT 432 Pro Leu Cys Val Ser Leu Lys Cys Thr Asp Leu Gly Asn Ala Thr Asn 130 135 140

ACC AAT AGT AGT AAT ACC AAT AGT AGT AGC GGG GAA ATG ATG ATG GAG 480 Thr Asn Ser Ser Asn Thr Asn Ser Ser Ser Gly Glu Met Met Met Glu 145 150 155 160

AAA GGA GAG ATA AAA AAC TGC TCT TTC AAT ATC AGC ACA AGC ATA AGA 528 Lys Gly Glu He Lys Asn Cys Ser Phe Asn He Ser Thr Ser He Arg 165 170 175

GGT AAG GTG CAG AAA GAA TAT GCA TTT TTT TAT AAA CTT GAT ATA ATA 576 Gly Lys Val Gin Lys Glu Tyr Ala Phe Phe Tyr Lys Leu Asp He He 180 185 190

CCA ATA GAT AAT GAT ACT ACC AGC TAT ACG TTG ACA AGT TGT AAC ACC 624 Pro He Asp Asn Asp Thr Thr Ser Tyr Thr Leu Thr Ser Cys Asn Thr 195 200 205 TCA GTC ATT ACA CAG GCC TGT CCA AAG GTA TCC TTT GAG CCA ATT CCC 672 Ser Val He Thr Gin Ala Cys Pro Lys Val Ser Phe Glu Pro He Pro

210 215 220

ATA CAT TAT TGT GCC CCG GCT GGT TTT GCG ATT CTA AAA TGT AAT AAT 720 He His Tyr Cys Ala Pro Ala Gly Phe Ala He Leu Lys Cys Asn Asn

225 230 235 240

AAG ACG TTC AAT GGA ACA GGA CCA TGT ACA AAT GTC AGC ACA GTA CAA 768 Lys Thr Phe Asn Gly Thr Gly Pro Cys Thr Asn Val Ser Thr Val Gin

245 250 255

TGT ACA CAT GGA ATT AGG CCA GTA GTA TCA ACT CAA CTG CTG TTG AAT 816

Cys Thr His Gly He Arg Pro Val Val Ser Thr Gin Leu Leu Leu Asn

260 265 270

GGC AGT CTA GCA GAA GAA GAG GTA GTA ATT AGA TCT GCC AAT TTC ACA 864

Gly Ser Leu Ala Glu Glu Glu Val Val He Arg Ser Ala Asn Phe Thr

275 280 285

GAC AAT GCT AAA ACC ATA ATA GTA CAG CTG AAC CAA TCT GTA GAA ATT 912

Asp Asn Ala Lys Thr He He Val Gin Leu Asn Gin Ser Val Glu He

290 295 300

AAT TGT ACA GGT GCT GGA CAT TGT AAC ATT AGT AGA GCA AAA TGG AAT 960

Asn Cys Thr Gly Ala Gly His Cys Asn He Ser Arg Ala Lys Trp Asn

305 310 315 320

GCC ACT TTA AAA CAG ATA GCT AGC AAA TTA AGA GAA CAA TTT GGA AAT 1008

Ala Thr Leu Lys Gin He Ala Ser Lys Leu Arg Glu Gin Phe Gly Asn

325 330 335

AAT AAA ACA ATA ATC TTT AAG CAA TCC TCA GGA GGG GAC CCA GAA ATT 1056

Asn Lys Thr He He Phe Lys Gin Ser Ser Gly Gly Asp Pro Glu He

340 345 350

GTA ACG CAC AGT TTT AAT TGT GGA GGG GAA TTT TTC TAC TGT AAT TCA 1104

Val Thr His Ser Phe Asn Cys Gly Gly Glu Phe Phe Tyr Cys Asn Ser

355 360 365

ACA CAA CTG TTT AAT AGT ACT TGG TTT AAT AGT ACT TGG AGT ACT GAA 1152

Thr Gin Leu Phe Asn Ser Thr Trp Phe Asn Ser Thr Trp Ser Thr Glu

370 375 380

GGG TCA AAT AAC ACT GAA GGA AGT GAC ACA ATC ACA CTC CCA TGC AGA 1200

Gly Ser Asn Asn Thr Glu Gly Ser Asp Thr He Thr Leu Pro Cys Arg

385 390 395 400

ATA AAA CAA TTT ATA AAC ATG TGG CAG GAA GTA GGA AAA GCA ATG TAT 1248

He Lys Gin Phe He Asn Met Trp Gin Glu Val Gly Lys Ala Met Tyr

405 410 415

GCC CCT CCC ATC AGC GGA CAA ATT AGA TGT TCA TCA AAT ATT ACA GGG 1296

Ala Pro Pro He Ser Gly Gin He Arg Cys Ser Ser Asn He Thr Gly

420 425 430

CTG CTA TTA ACA AGA GAT GGT GGT AAT AAC AAC AAT GGG TCC GAG ATC 1344

Leu Leu Leu Thr Arg Asp Gly Gly Asn Asn Asn Asn Gly Ser Glu He

435 440 445

TTC AGA CCT GGA GGA GGA GAT ATG AGG GAC AAT TGG AGA AGT GAA TTA 1392

Phe Arg Pro Gly Gly Gly Asp Met Arg Asp Asn Trp Arg Ser Glu Leu

450 455 460

TAT AAA TAT AAA GTA GTA AAA ATT GAA CCA TTA GGA GTA GCA CCC ACC 1440

Tyr Lys Tyr Lys Val Val Lys He Glu Pro Leu Gly Val Ala Pro Thr

465 470 475 480

AAG GCA AAG AGA AGA GTG GTG CAG AGA GAA AAA T GAGCGGCCGC 1484 Lys Ala Lys Arg Arg Val Val Gin Arg Glu Lys 485 490

(2) INFORMATION FOR SEQ ID N0:18:

(i) SEQUENCE CHARACTE ISTICS:

(A) LENGTH: 491 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

Met Asp Ala Met Lys Arg Gly Leu Cys Cys Val Leu Leu Leu Cys Gly 1 5 10 15

Ala Val Phe Val Ser Pro Ser Gin Glu He His Ala Arg Phe Arg Arg 20 25 30

Gly Ala Arg Thr Glu Lys Leu Trp Vat Thr Val Tyr Tyr Gly Val Pro 35 40 45

Val Trp Lys Glu Ala Thr Thr Thr Leu Phe Cys Ala Ser Asp Ala Lys 50 55 60

Ala Tyr Asp Thr Glu Val His Asn Val Trp Ala Thr His Ala Cys Val 65 70 75 80

Pro Thr Asp Pro Asn Pro Gin Glu Val Val Leu Val Asn Val Thr Glu 85 90 95

Asn Phe Asn Met Trp Lys Asn Asp Met Val Glu Gin Met His Glu Asp 100 105 110

He He Ser Leu Trp Asp Gin Ser Leu Lys Pro Cys Val Lys Leu Thr 115 120 125

Pro Leu Cys Val Ser Leu Lys Cys Thr Asp Leu Gly Asn Ala Thr Asn 130 135 140

Thr Asn Ser Ser Asn Thr Asn Ser Ser Ser Gly Glu Met Met Met Glu 145 150 155 160

Lys Gly Glu He Lys Asn Cys Ser Phe Asn He Ser Thr Ser He Arg 165 170 175

Gly Lys Val Gin Lys Glu Tyr Ala Phe Phe Tyr Lys Leu Asp He He 180 185 190

Pro He Asp Asn Asp Thr Thr Ser Tyr Thr Leu Thr Ser Cys Asn Thr 195 200 205

Ser Val He Thr Gin Ala Cys Pro Lys Val Ser Phe Glu Pro He Pro 210 215 220

He His Tyr Cys Ala Pro Ala Gly Phe Ala He Leu Lys Cys Asn Asn 225 230 235 240

Lys Thr Phe Asn Gly Thr Gly Pro Cys Thr Asn Val Ser Thr Val Gin 245 250 255

Cys Thr His Gly He Arg Pro Val Val Ser Thr Gin Leu Leu Leu Asn 260 265 270

Gly Ser Leu Ala Glu Glu Glu Val Val He Arg Ser Ala Asn Phe Thr 275 280 285 Asp Asn Ala Lys Thr He He Val Gin Leu Asn Gin Ser Val Glu He 290 295 300

Asn Cys Thr Gly Ala Gly His Cys Asn He Ser Arg Ala Lys Trp Asn 305 310 315 320

Ala Thr Leu Lys Gin He Ala Ser Lys Leu Arg Glu Gin Phe Gly Asn 325 330 335

Asn Lys Thr He He Phe Lys Gin Ser Ser Gly Gly Asp Pro Glu He 340 345 350

Val Thr His Ser Phe Asn Cys Gly Gly Glu Phe Phe Tyr Cys Asn Ser 355 360 365

Thr Gin Leu Phe Asn Ser Thr Trp Phe Asn Ser Thr Trp Ser Thr Glu 370 375 380

Gly Ser Asn Asn Thr Glu Gly Ser Asp Thr He Thr Leu Pro Cys Arg 385 390 395 400

He Lys Gin Phe He Asn Met Trp Gin Glu Val Gly Lys Ala Met Tyr 405 410 415

Ala Pro Pro He Ser Gly Gin He Arg Cys Ser Ser Asn He Thr Gly 420 425 430

Leu Leu Leu Thr Arg Asp Gly Gly Asn Asn Asn Asn Gly Ser Glu He 435 440 445

Phe Arg Pro Gly Gly Gly Asp Met Arg Asp Asn Trp Arg Ser Glu Leu 450 455 460

Tyr Lys Tyr Lys Val Val Lys He Glu Pro Leu Gly Val Ala Pro Thr 465 470 475 480

Lys Ala Lys Arg Arg Val Val Gin Arg Glu Lys 485 490

(2) INFORMATION FOR SEQ ID NO:19:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1448 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 1..1439 (D) OTHER INFORMATION:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

GCA GTC TTC GTT TCG CCC AGC CAG GAA ATC CAT GCC CGA TTC AGA AGA 96 Ala Val Phe Val Ser Pro Ser Gin Glu He His Ala Arg Phe Arg Arg 20 25 30 *

GGC GGC AGA GTA GAA AAG TTG TGG GTC ACA GTC TAT TAT GGG GTA CCT 144 Gly Gly Arg Val Glu Lys Leu Trp Val Thr Val Tyr Tyr Gly Val Pro 35 40 45 GTG TGG AAA GAA GCA ACC ACC ACT CTA TTT TGT GCA TCA GAT GCT AAA 192 Val Trp Lys Glu Ala Thr Thr Thr Leu Phe Cys Ala Ser Asp Ala Lys 50 55 60

CAT TTT AAC ATG TGG AAA AAT AAC ATG GTA GAA CAG ATG CAG GAG GAT 336 His Phe Asn Met Trp Lys Asn Asn Met Val Glu Gin Met Gin Glu Asp 100 105 110

GTA CAG CTG AAA GAA TCT GTA GAA ATT AAT TGT ACA GGT GCT GGA CAT 912 Val Gin Leu Lys Glu Ser Val Glu He Asn Cys Thr Gly Ala Gly His 290 295 300

TGT AAC ATT AGT AGA GCA AAA TGG AAT GAC ACT TTA AAA CAG ATA GTT 960 Cys Asn He Ser Arg Ala Lys Trp Asn Asp Thr Leu Lys Gin He Val 305 310 315 320

ATA AAA TTA AGA GAA CAA TTT GAG AAT AAA ACA ATA GTC TTT AAT CAC 1008 He Lys Leu Arg Glu Gin Phe Glu Asn Lys Thr He Val Phe Asn His 325 330 335

TCC TCA GGA GGG GAC CCA GAA ATT GTA ATG CAC AGT TTT AAT TGT GGA 1056 Ser Ser Gly Gly Asp Pro Glu He Val Met His Ser Phe Asn Cys Gly 340 345 350

GGA GAA TTT TTC TAC TGT AAT TCA ACA CAA CTG TTT AAT AGT ACT TGG 1104 Gly Giu Phe Phe Tyr Cys Asn Ser Thr Gin Leu Phe Asn Ser Thr Trp 355 360 365

AAT AAT AAT ACT GAA GGG TCA AAT AAC ACT GAA GGA AAT ACT ATC ACA 1152 Asn Asn Asn Thr Glu Gly Ser Asn Asn Thr Glu Gly Asn Thr He Thr 370 375 380

CTC CCA TGC AGA ATA AAA CAA ATT ATA AAC ATG TGG CAG GAA GTA GGA 1200 Leu Pro Cys Arg He Lys Gin He He Asn Met Trp Gin Glu Val Gly 385 390 395 400

AAA GCA ATG TAT GCC CCT CCC ATC AGA GGA CAA ATT AGA TGT TCA TCA 1248 Lys Ala Met Tyr Ala Pro Pro He Arg Gly Gin He Arg Cys Ser Ser 405 410 415

AAT ATT ACA GGG CTG CTA TTA ACA AGA GAT GGT GGT ATT AAT GAG AAT 1296 Asn He Thr Gly Leu Leu Leu Thr Arg Asp Gly Gly He Asn Glu Asn 420 425 430

GGG ACC GAG ATC TTC AGA CCT GGA GGA GGA GAT ATG AGG GAC AAT TGG 1344 Gly Thr Glu He Phe Arg Pro Gly Gly Gly Asp Met Arg Asp Asn Trp 435 440 445

AGA AGT GAA TTA TAT AAA TAT AAA GTA GTA AAA ATT GAA CCA TTA GGA 1392 Arg Ser Glu Leu Tyr Lys Tyr Lys Val Val Lys He Glu Pro Leu Gly 450 455 460

GTA GCA CCC ACC AAG GCA AAG AGA AGA GTG GTG CAA AGA GAA AAA TG 1439 Val Ala Pro Thr Lys Ala Lys Arg Arg Val Val Gin Arg Glu Lys 465 470 475

AGCGGCCGC 1448

(2) INFORMATION FOR SEQ ID NO:20:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 479 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

Met Asp Ala Met Lys Arg Gly Leu Cys Cys Val Leu Leu Leu Cys Gly

1 5 10 15

Ala Val Phe Val Ser Pro Ser Gin Glu He His Ala Arg Phe Arg Arg 20 25 30

Gly Gly Arg Val Glu Lys Leu Trp Val Thr Val Tyr Tyr Gly Val Pro 35 40 45

Val Trp Lys Glu Ala Thr Thr Thr Leu Phe Cys Ala Ser Asp Ala Lys 50 55 60

Ala Tyr Asp Thr Glu Val His Asn Val Trp Ala Thr His Ala Cys Val 65 70 75 80

Pro Thr Asp Pro Asn Pro Gin Glu Val Val Leu Glu Asn Val Thr Glu 85 90 95

His Phe Asn Met Trp Lys Asn Asn Met Val Glu Gin Met Gin Glu Asp 100 105 110

He He Ser Leu Trp Asp Gin Ser Leu Lys Pro Cys Val Lys Leu Thr 115 120 125

Pro Leu Cys Val Thr Leu Asn Cys Lys Asp Val Asn Ala Thr Asn Thr 130 135 140

Thr Asn Asp Ser Glu Gly Thr Met Glu Arg Gly Glu He Lys Asn Cys 145 150 155 160

Ser Phe Asn He Thr Thr Ser He Arg Asp Glu Val Gin Lys Glu Tyr 165 170 175

Ala Leu Phe Tyr Lys Leu Asp Val Val Pro He Asp Asn Asn Asn Thr 180 185 190

Ser Tyr Arg Leu He Ser Cys Asp Thr Ser Val He Thr Gin Ala Cys 195 200 205

Pro Lys He Ser Phe Glu Pro He Pro He His Tyr Cys Ala Pro Ala 210 215 220

Gly Phe Ala He Leu Lys Cys Asn Asp Lys Thr Phe Asn Gly Lys Gly 225 230 235 240

Pro Cys Lys Asn Val Ser Thr Val Gin Cys Thr His Gly He Arg Pro 245 250 255

Val Val Ser Thr Gin Leu Leu Leu Asn Gly Ser Leu Ala Glu Glu Glu 260 265 270

Vat Val He Arg Ser Asp Asn Phe Thr Asn Asn Ala Lys Thr He He 275 280 285

Val Gin Leu Lys Glu Ser Val Glu He Asn Cys Thr Gly Ala Gly His 290 295 300

Cys Asn He Ser Arg Ala Lys Trp Asn Asp Thr Leu Lys Gin He Val 305 310 315 320

He Lys Leu Arg Glu Gin Phe Glu Asn Lys Thr He Val Phe Asn His 325 330 335

Ser Ser Gly Gly Asp Pro Glu He Val Met His Ser Phe Asn Cys Gly 340 345 350

Gly Glu Phe Phe Tyr Cys Asn Ser Thr Gin Leu Phe Asn Ser Thr Trp 355 360 365

Asn Asn Asn Thr Glu Gly Ser Asn Asn Thr Glu Gly Asn Thr He Thr 370 375 380

Leu Pro Cys Arg He Lys Gin He He Asn Met Trp Gin Glu Val Gly 385 390 395 400

Lys Ala Met Tyr Ala Pro Pro He Arg Gly Gin He Arg Cys Ser Ser 405 410 415

Asn He Thr Gly Leu Leu Leu Thr Arg Asp Gly Gly He Asn Glu Asn 420 425 430

Gly Thr Glu He Phe Arg Pro Gly Gly Gly Asp Met Arg Asp Asn Trp 435 440 445

Arg Ser Glu Leu Tyr Lys Tyr Lys Val Val Lys He Glu Pro Leu Gly 450 455 460

Val Ala Pro Thr Lys Ala Lys Arg Arg Val Val Gin Arg Glu Lys 465 470 475

(2) INFORMATION FOR SE^Q ID N0:21:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1484 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 1..1454 (D) OTHER INFORMATION:

(xi) SEQUENCE DESCRIPTION: SE^Q ID NO:21:

ATG GAT GCA ATG AAG AGA GGG CTC TGC TGT GTG CTG CTG CTG TGT GGA 48 Met Asp Ala Met Lys Arg Gty Leu Cys Cys Val Leu Leu Leu Cys Gly 1 5 10 15

CCA ATA GAT AAT GAT ACT ACC AGC TAT ACG TTG ACA AGT TGT AAC ACC 624 p o He Asp Asn Asp Thr Thr Ser Tyr Thr Leu Thr Ser Cys Asn Thr 195 200 205

TCA GTC ATT ACA CAG GCC TGT CCA AAG GTA TCC TTT GAG CCA ATT CCC 672

Ser Val He Thr Gin Ala Cys Pro Lys Val Ser Phe Glu Pro He Pro

210 215 220

225 230 235 240

AAG ACG TTC AAT GGA ACA GGA CCA TGT ACA AAT GTC AGC ACA GTA CAA 768 Lys Thr Phe Asn Gly Thr Gly Pro Cys Thr Asn Val Ser Thr Val Gin 245 250 255

TGT ACA CAT GGA ATT AGG CCA GTA GTA TCA ACT CAA CTG CTG TTG AAT 816

Cys Thr His Gly He Arg Pro Val Val Ser Thr Gin Leu Leu Leu Asn 260 265 270

GGC AGT CTA GCA GAA GAA GAG GTA GTA ATT AGA TCT GCC AAT TTC ACA 864

Gly Ser Leu Ala Glu Glu Glu Val Vat He Arg Ser Ala Asn Phe Thr 275 280 285

GAC AAT GCT AAA ACC ATA ATA GTA CAG CTG AAC CAA TCT GTA GAA ATT 912

Asp Asn Ala Lys Thr He He Val Gin Leu Asn Gin Ser Val Glu He

290 295 300

AAT TGT ACA GGT GCT GGA CAT TGT AAC ATT AGT AGA GCA AAA TGG AAT 960

Asn Cys Thr Gly Ala Gty His Cys Asn He Ser Arg Ala Lys Trp Asn

305 310 315 320

GCC ACT TTA AAA CAG ATA GCT AGC AAA TTA AGA GAA CAA TTT GGA AAT 1008

Ala Thr Leu Lys Gin He Ala Ser Lys Leu Arg Glu Gin Phe Gly Asn 325 330 335

AAT AAA ACA ATA ATC TTT AAG CAA TCC TCA GGA GGG GAC CCA GAA ATT 1056

Asn Lys Thr He He Phe Lys Gin Ser Ser Gly Gly Asp Pro Glu He 340 345 350

GTA ACG CAC AGT TTT AAT TGT GGA GGG GAA TTT TTC TAC TGT AAT TCA 1104

Vat Thr His Ser Phe Asn Cys Gly Gly Glu Phe Phe Tyr Cys Asn Ser 355 360 365

ACA CAA CTG TTT AAT AGT ACT TGG TTT AAT AGT ACT TGG AGT ACT GAA 1152

Thr Gin Leu Phe Asn Ser Thr Trp Phe Asn Ser Thr Trp Ser Thr Glu

370 375 380

GGG TCA AAT AAC ACT GAA GGA AGT GAC ACA ATC ACA CTC CCA TGC AGA 1200

Gly Ser Asn Asn Thr Glu Gly Ser Asp Thr He Thr Leu Pro Cys Arg

385 390 395 400

ATA AAA CAA TTT ATA AAC ATG GTG CAG GAA GTA GGA AAA GCA ATG TAT 1248

He Lys Gin Phe He Asn Met Val Gin Glu Val Gly Lys Ala Met Tyr 405 410 415

GCC CCT CCC ATC AGC GGA CAA ATT AGA TGT TCA TCA AAT ATT ACA GGG 1296

Ala Pro Pro He Ser Gly Gin He Arg Cys Ser Ser Asn He Thr Gly 420 425 430

CTG CTA TTA ACA AGA GAT GGT GGT AAT AAC AAC AAT GGG TCC GAG ATC 1344

Leu Leu Leu Thr Arg Asp Gly Gly Asn Asn Asn Asn Gly Ser Glu He 435 440 445

TTC AGA CCT GGA GGA GGA GAT ATG AGG GAC AAT TGG AGA AGT GAA TTA 1392

Phe Arg Pro Gly Gly Gly Asp Met Arg Asp Asn Trp Arg Ser Glu Leu

450 455 460 TAT AAA TAT AAA GTA GTA AAA ATT GAA CCA TTA GGA GTA GCA CCC ACC 1440 Tyr Lys Tyr Lys Val Val Lys He Gtu Pro Leu Gly Val Ala Pro Thr 465 470 475 480

AAG GCA AAG AGA AG AGTGGTGCAG AGAGAAAAAT GAGCGGCCGC 1484

Lys Ata Lys Arg

(2) INFORMATION FOR SE^Q ID NO:22:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 484 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

Met Asp Ala Met Lys Arg Gly Leu Cys Cys Val Leu Leu Leu Cys Gly 1 5 10 15

Ala Val Phe Vat Ser Pro Ser Gin Glu He His Ala Arg Phe Arg Arg 20 25 30

Gly Ala Arg Thr Glu Lys Leu Trp Val Thr Val Tyr Tyr Gly Val Pro 35 40 45

Val Trp Lys Glu Ala Thr Thr Thr Leu Phe Cys Ala Ser Asp Ala Lys 50 55 60

Ala Tyr Asp Thr Glu Val His Asn Val Trp Ala Thr His Ala Cys Val 65 70 75 80

Pro Thr Asp Pro Asn Pro Gin Glu Val Vat Leu Val Asn Vat Thr Glu 85 90 95

Asn Phe Asn Met Trp Lys Asn Asp Met Val Glu Gin Met His Glu Asp 100 105 110

He He Ser Leu Trp Asp Gin Ser Leu Lys Pro Cys Val Lys Leu Thr 115 120 125

Pro Leu Cys Val Ser Leu Lys Cys Thr Asp Leu Gly Asn Ala Thr Asn 130 135 140

Thr Asn Ser Ser Asn Thr Asn Ser Ser Ser Gly Glu Met Met Met Glu 145 150 155 160

Lys Gly Glu He Lys Asn Cys Ser Phe Asn He Ser Thr Ser He Arg 165 170 175

Gly Lys Val Gin Lys Glu Tyr Ala Phe Phe Tyr Lys Leu Asp He He 180 185 190

Pro He Asp Asn Asp Thr Thr Ser Tyr Thr Leu Thr Ser Cys Asn Thr 195 200 205

Ser Val He Thr Gin Ala Cys Pro Lys Val Ser Phe Glu Pro He Pro 210 215 220

He His Tyr Cys Ala Pro Ala Gly Phe Ala He Leu Lys Cys Asn Asn 225 230 235 240

Lys Thr Phe Asn Gly Thr Gly Pro Cys Thr Asn Vat Ser Thr Val Gin 245 250 255

Cys Thr His Gly He Arg Pro Val Val Ser Thr Gin Leu Leu Leu Asn 260 265 270

Gly Ser Leu Ata Gtu Gtu Glu Vat Vat He Arg Ser Ata Asn Phe Thr 275 280 285

Asp Asn Ata Lys Thr He He Vat Gin Leu Asn Gtn Ser Vat Glu He 290 295 300

Asn Cys Thr Gty Ala Gly His Cys Asn He Ser Arg Ala Lys Trp Asn 305 310 315 320

Ala Thr Leu Lys Gin He Ata Ser Lys Leu Arg Gtu Gtn Phe Gty Asn 325 330 335

Asn Lys Thr He He Phe Lys Gin Ser Ser Gly Gly Asp Pro Glu He 340 345 350

Val Thr His Ser Phe Asn Cys Gly Gly Gtu Phe Phe Tyr Cys Asn Ser 355 360 365

Thr Gin Leu Phe Asn Ser Thr Trp Phe Asn Ser Thr Trp Ser Thr Glu 370 375 380

Gty Ser Asn Asn Thr Glu Gly Ser Asp Thr He Thr Leu Pro Cys Arg 385 390 395 400

He Lys Gin Phe He Asn Met Vat Gin Glu Vat Gly Lys Ala Met Tyr 405 410 415

Ata Pro Pro He Ser Gly Gin He Arg Cys Ser Ser Asn He Thr Gly 420 425 430

Leu Leu Leu Thr Arg Asp Gly Gly Asn Asn Asn Asn Gly Ser Glu He 435 440 445

Phe Arg Pro Gly Gly Gly Asp Met Arg Asp Asn Trp Arg Ser Glu Leu 450 455 460

Tyr Lys Tyr Lys Val Val Lys He Glu Pro Leu Gty Val Ala Pro Thr 465 470 475 480

Lys Ala Lys Arg

(2) INFORMATION FOR SEQ ID NO:23:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1448 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 1..1438 (D) OTHER INFORMATION:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

GCA GTC TTC GTT TCG CCC AGC CAG GAA ATC CAT GCC CGA TTC AGA AGA 96 Ala Val Phe Val Ser Pro Ser Gin Glu He His Ala Arg Phe Arg Arg 20 25 30 GGC GGC AGA GTA GAA AAG TTG TGG GTC ACA GTC TAT TAT GGG GTA CCT 144 Gly Gty Arg Val Glu Lys Leu Trp Val Thr Val Tyr Tyr Gty Val Pro 35 40 45

GTG TGG AAA GAA GCA ACC ACC ACT CTA TTT TGT GCA TCA GAT GCT AAA 192 Vat Trp Lys Gtu Ala Thr Thr Thr Leu Phe Cys Ata Ser Asp Ala Lys 50 55 60

GCA TAT GAT ACA GAG GTA CAT AAT GTT TGG GCC ACA CAT GCC TGT GTA 240 Ala Tyr Asp Thr Glu Vat His Asn Val Trp Ata Thr His Ala Cys Vat 65 70 75 80

CCC ACA GAC CCC AAC CCA CAA GAA GTA GTA TTG GAA AAT GTA ACA GAA 288 Pro Thr Asp Pro Asn Pro Gtn Glu Val Val Leu Glu Asn Val Thr Glu 85 90 95

CAT TTT AAC ATG TGG AAA AAT AAC ATG GTA GAA CAG ATG CAG GAG GAT 336 His Phe Asn Met Trp Lys Asn Asn Met Vat Gtu Gin Met Gin Glu Asp 100 105 110

AGC TAT AGG TTG ATA AGT TGT GAC ACC TCA GTC ATT ACA CAG GCC TGT 624 Ser Tyr Arg Leu He Ser Cys Asp Thr Ser Val He Thr Gtn Ala Cys 195 200 205

CCA AAG ATA TCC TTT GAG CCA ATT CCC ATA CAT TAT TGT GCC CCG GCT 672 Pro Lys He Ser Phe Gtu Pro He Pro He His Tyr Cys Ala Pro Ala 210 215 220

TGT AAC ATT AGT AGA GCA AAA TGG AAT GAC ACT TTA AAA CAG ATA GTT 960 Cys Asn He Ser Arg Ala Lys Trp Asn Asp Thr Leu Lys Gtn He Vat 305 310 315 320

ATA AAA TTA AGA GAA CAA TTT GAG AAT AAA ACA ATA GTC TTT AAT CAC 1008 He Lys Leu Arg Gtu Gtn Phe Gtu Asn Lys Thr He Val Phe Asn His 325 330 335

TCC TCA GGA GGG GAC CCA GAA ATT GTA ATG CAC AGT TTT AAT TGT GGA 1056 Ser Ser Gty Gty Asp Pro Gtu He Vat Met His Ser Phe Asn Cys Gly 340 345 350

GGA GAA TTT TTC TAC TGT AAT TCA ACA CAA CTG TTT AAT AGT ACT TGG 1104 Gty Gtu Phe Phe Tyr Cys Asn Ser Thr Gin Leu Phe Asn Ser Thr Trp 355 360 365

AAT AAT AAT ACT GAA GGG TCA AAT AAC ACT GAA GGA AAT ACT ATC ACA 1152 Asn Asn Asn Thr Glu Gty Ser Asn Asn Thr Gtu Gly Asn Thr He Thr 370 375 380

CTC CCA TGC AGA ATA AAA CAA ATT ATA AAC ATG GTG CAG GAA GTA GGA 1200 Leu Pro Cys Arg He Lys Gin He He Asn Met Vat Gin Glu Vat Gty 385 390 395 400

AAA GCA ATG TAT GCC CCT CCC ATC AGA GGA CAA ATT AGA TGT TCA TCA 1248 Lys Ala Met Tyr Ala Pro Pro He Arg Gty Gin He Arg Cys Ser Ser 405 410 415

GGG ACC GAG ATC TTC AGA CCT GGA GGA GGA GAT ATG AGG GAC AAT TGG 1344 Gly Thr Glu He Phe Arg Pro Gty Gly Gly Asp Met Arg Asp Asn Trp 435 440 445

AGA AGT GAA TTA TAT AAA TAT AAA GTA GTA AAA ATT GAA CCA TTA GGA 1392 Arg Ser Gtu Leu Tyr Lys Tyr Lys Val Vat Lys He Gtu Pro Leu Gly 450 455 460

GTA GCA CCC ACC AAG GCA AAG AGA AGA GTG GTG CAA AGA GAA AAA T 1438 Val Ala Pro Thr Lys Ala Lys Arg Arg Val Val Gin Arg Glu Lys 465 470 475

GAGCGGCCGC 1448

(2) INFORMATION FOR SEQ ID NO:24:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 479 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

Met Asp Ala Met Lys Arg Gly Leu Cys Cys^* Val Leu Leu Leu Cys Gty 1 5 10 15

Ala Val Phe Val Ser Pro Ser Gin Glu He His Ala Arg Phe Arg Arg 20 25 30

Gly Gly Arg Val Glu Lys Leu Trp Val Thr Val Tyr Tyr Gly Val Pro 35 40 45

Val Trp Lys Glu Ala Thr Thr Thr Leu Phe Cys Ala Ser Asp Ala Lys 50 55 60 Ala Tyr Asp Thr Glu Val His Asn Val Trp Ata Thr His Ala Cys Vat 65 70 75 80

Pro Thr Asp Pro Asn Pro Gin Gtu Vat Vat Leu Gtu Asn Val Thr Gtu 85 90 95

His Phe Asn Met Trp Lys Asn Asn Met Vat Glu Gtn Met Gin Gtu Asp 100 105 110

He He Ser Leu Trp Asp Gtn Ser Leu Lys Pro Cys Vat Lys Leu Thr 115 120 125

Pro Leu Cys Val Thr Leu Asn Cys Lys Asp Vat Asn Ala Thr Asn Thr 130 135 140

Thr Asn Asp Ser Gtu Gly Thr Met Gtu Arg Gly Gtu He Lys Asn Cys 145 150 155 160

Ser Phe Asn He Thr Thr Ser He Arg Asp Gtu Val Gin Lys Glu Tyr 165 170 175

Ala Leu Phe Tyr Lys Leu Asp Val Vat Pro He Asp Asn Asn Asn Thr 180 185 190

Ser Tyr Arg Leu He Ser Cys Asp Thr Ser Vat He Thr Gin Ala Cys 195 200 205

Pro Lys He Ser Phe Glu Pro He Pro He His Tyr Cys Ala Pro Ala 210 215 220

Gty Phe Ala He Leu Lys Cys Asn Asp Lys Thr Phe Asn Gly Lys Gty 225 230 235 240

Pro Cys Lys Asn Val Ser Thr Val Gin Cys Thr His Gly He Arg Pro 245 250 255

Val Val Ser Thr Gin Leu Leu Leu Asn Gly Ser Leu Ala Glu Glu Glu 260 265 270

Val Vat He Arg Ser Asp Asn Phe Thr Asn Asn Ala Lys Thr He He 275 280 285

Val Gin Leu Lys Glu Ser Val Glu He Asn Cys Thr Gly Ala Gly His 290 295 300

Cys Asn He Ser Arg Ala Lys Trp Asn Asp Thr Leu Lys Gin He Val 305 310 315 320

He Lys Leu Arg Glu Gin Phe Glu Asn Lys Thr He Val Phe Asn His 325 330 335

Ser Ser Gly Gly Asp Pro Glu He Val Met His Ser Phe Asn Cys Gly 340 345 350

Gly Glu Phe Phe Tyr Cys Asn Ser Thr Gin Leu Phe Asn Ser Thr Trp 355 360 365

Asn Asn Asn Thr Glu Gly Ser Asn Asn Thr Glu Gly Asn Thr He Thr 370 375 380

Leu Pro Cys Arg He Lys Gin He He Asn Met Vat Gin Glu Val Gly 385 390 395 400

Lys Ala Met Tyr Ala Pro Pro He Arg Gly Gin He Arg Cys Ser Ser 405 410 415

Asn He Thr Gly Leu Leu Leu Thr Arg Asp Gly Gly He Asn Glu Asn 420 425 430 Gly Thr Glu He Phe Arg Pro Gly Gty Gly Asp Met Arg Asp Asn Trp 435 440 445

Arg Ser Gtu Leu Tyr Lys Tyr Lys Val Vat Lys He Glu Pro Leu Gty 450 455 460

Val Ata Pro Thr Lys Ala Lys Arg Arg Vat Val Gtn Arg Glu Lys 465 470 475

(2) INFORMATION FOR SEQ ID NO:25:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1571 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 1..1567 (D) OTHER INFORMATION:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

GGC GCC AGA ACA GAA AAA TTG TGG GTC ACA GTC TAT TAT GGG GTA CCT 144 Gly Ata Arg Thr Glu Lys Leu Trp Val Thr Val Tyr Tyr Gly Val Pro 35 40 45

GTG TGG AAG GAA GCA ACC ACC ACT CTA TTT TGT GCA TCA GAT GCT AAA 192 Vat Trp Lys Glu Ala Thr Thr Thr Leu Phe Cys Ala Ser Asp Ala Lys 50 55 60

GGT AAG GTG CAG AAA GAA TAT GCA TTT TTT TAT AAA CTT GAT ATA ATA 576 Gty Lys Vat Gtn Lys Glu Tyr Ala Phe Phe Tyr Lys Leu Asp He He 180 185 190

CCA ATA GAT AAT GAT ACT ACC AGC TAT ACG TTG ACA AGT TGT AAC ACC 624 Pro He Asp Asn Asp Thr Thr Ser Tyr Thr Leu Thr Ser Cys Asn Thr 195 200 205

TCA GTC ATT ACA CAG GCC TGT CCA AAG GTA TCC TTT GAG CCA ATT CCC 672 Ser Vat He Thr Gtn Ala Cys Pro Lys Vat Ser Phe Glu Pro He Pro 210 215 220

ATA CAT TAT TGT GCC CCG GCT GGT TTT GCG ATT CTA AAA TGT AAT AAT 720 He His Tyr Cys Ala Pro Ata Gly Phe Ala He Leu Lys Cys Asn Asn 225 230 235 240

AAG ACG TTC AAT GGA ACA GGA CCA TGT ACA AAT GTC AGC ACA GTA CAA 768 Lys Thr Phe Asn Gly Thr Gly Pro Cys Thr Asn Val Ser Thr Vat Gin 245 250 255

TGT ACA CAT GGA ATT AGG CCA GTA GTA TCA ACT CAA CTG CTG TTG AAT 816 Cys Thr His Gly He Arg Pro Vat Val Ser Thr Gin Leu Leu Leu Asn 260 265 270

GGC AGT CTA GCA GAA GAA GAG GTA GTA ATT AGA TCT GCC AAT TTC ACA 864 Gly Ser Leu Ala Glu Glu Glu Val Val He Arg Ser Ala Asn Phe Thr 275 280 285

GAC AAT GCT AAA ACC ATA ATA GTA CAG CTG AAC CAA TCT GTA GAA ATT 912 Asp Asn Ala Lys Thr He He Val Gin Leu Asn Gin Ser Val Glu He 290 295 300

AAT TGT ACA AGA CCC AAC AAC AAT ACA AGA AAA AGT ATC CGT ATC CAG 960 Asn Cys Thr Arg Pro Asn Asn Asn Thr Arg Lys Ser He Arg He Gin 305 310 315 320

AGG GGA CCA GGG AGA GCA TTT GTT ACA ATA GGA AAA ATA GGA AAT ATG 1008 Arg Gly Pro Gly Arg Ala Phe Val Thr He Gly Lys He Gly Asn Met 325 330 335

AGA CAA GCA CAT TGT AAC ATT AGT AGA GCA AAA TGG AAT GCC ACT TTA 1056 Arg Gin Ala His Cys Asn He Ser Arg Ala Lys Trp Asn Ala Thr Leu 340 345 350

AAA CAG ATA GCT AGC AAA TTA AGA GAA CAA TTT GGA AAT AAT AAA ACA 1104 Lys Gin He Ata Ser Lys Leu Arg Glu Gin Phe Gly Asn Asn Lys Thr 355 360 365

ATA ATC TTT AAG CAA TCC TCA GGA GGG GAC CCA GAA ATT GTA ACG CAC 1152 He He Phe Lys Gin Ser Ser Gly Gly Asp Pro Glu He Val Thr His 370 375 380

AGT TTT AAT TGT GGA GGG GAA TTT TTC TAC TGT AAT TCA ACA CAA CTG 1200 Ser Phe Asn Cys Gly Gly Glu Phe Phe Tyr Cys Asn Ser Thr Gin Leu 385 390 395 400

TTT AAT AGT ACT TGG TTT AAT AGT ACT TGG AGT ACT GAA GGG TCA AAT 1248 Phe Asn Ser Thr Trp Phe Asn Ser Thr Trp Ser Thr Glu Gly Ser Asn 405 410 415

AAC ACT GAA GGA AGT GAC ACA ATC ACA CTC CCA TGC AGA ATA AAA CAA 1296 Asn Thr Glu Gly Ser Asp Thr He Thr Leu Pro Cys Arg He Lys Gin 420 425 430

TTT ATA AAC ATG GTG CAG GAA GTA GGA AAA GCA ATG TAT GCC CCT CCC 1344 Phe He Asn Met Val Gin Glu Val Gly Lys Ala Met Tyr Ala Pro Pro 435 440 445 ATC AGC GGA CAA ATT AGA TGT TCA TCA AAT ATT ACA GGG CTG CTA TTA 1392 He Ser Gty Gtn He Arg Cys Ser Ser Asn He Thr Gly Leu Leu Leu 450 455 460

ACA AGA GAT GGT GGT AAT AAC AAC AAT GGG TCC GAG ATC TTC AGA CCT 1440 Thr Arg Asp Gly Gty Asn Asn Asn Asn Gly Ser Glu He Phe Arg Pro 465 470 475 480

GGA GGA GGA GAT ATG AGG GAC AAT TGG AGA AGT GAA TTA TAT AAA TAT 1488 G.y Gly Gly Asp Met Arg Asp Asn Trp Arg Ser Glu Leu Tyr Lys Tyr 485 490 495

AAA GTA GTA AAA ATT GAA CCA TTA GGA GTA GCA CCC ACC AAG GCA AAG 1536 Lys Vat Vat Lys He Glu Pro Leu Gly Vat Ala Pro Thr Lys Ata Lys 500 505 510

AGA AGA GTG GTG CAG AGA GAA AAA TGA GCG G CCGC 1571

Arg Arg Val Val Gtn Arg Glu Lys 515 520

(2) INFORMATION FOR SEQ ID NO:26:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 522 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

Met Asp Ala Met Lys Arg Gly Leu Cys Cys Val Leu Leu Leu Cys Gly 1 5 10 15

Ata Val Phe Val Ser Pro Ser Gin Glu He His Ala Arg Phe Arg Arg 20 25 30

Gly Ala Arg Thr Glu Lys Leu Trp Val Thr Val Tyr Tyr Gly Val Pro 35 40 45

Val Trp Lys Glu Ala Thr Thr Thr Leu Phe Cys Ala Ser Asp Ala Lys 50 55 60

Ala Tyr Asp Thr Glu Val His Asn Val Trp Ala Thr His Ala Cys Val 65 70 75 80

Pro Thr Asp Pro Asn Pro Gin Glu Val Val Leu Val Asn Val Thr Glu 85 90 95

Asn Phe Asn Met Trp Lys Asn Asp Met Val Glu Gin Met His Glu Asp 100 105 110

He He Ser Leu Trp Asp Gin Ser Leu Lys Pro Cys Val Lys Leu Thr 115 120 125

Pro Leu Cys Val Ser Leu Lys Cys Thr Asp Leu Gly Asn Ala Thr Asn 130 135 140

Thr Asn Ser Ser Asn Thr Asn Ser Ser Ser Gly Glu Met Met Met Glu 145 150 155 160

Lys Gly Glu He Lys Asn Cys Ser Phe Asn He Ser Thr Ser He Arg 165 170 175

Gly Lys Val Gin Lys Glu Tyr Ala Phe Phe Tyr Lys Leu Asp He He 180 185 190

Pro He Asp Asn Asp Thr Thr Ser Tyr Thr Leu Thr Ser Cys Asn Thr 195 200 205

Ser Vat He Thr Gin Ata Cys Pro Lys Val Ser Phe Glu Pro He Pro 210 215 220

He His Tyr Cys Ala Pro Ala Gly Phe Ala He Leu Lys Cys Asn Asn 225 230 235 240

Lys Thr Phe Asn Gly Thr Gly Pro Cys Thr Asn Val Ser Thr Val Gin 245 250 255

Cys Thr His Gly He Arg Pro Vat Val Ser Thr Gin Leu Leu Leu Asn 260 265 270

Gly Ser Leu Ala Glu Glu Glu Val Val He Arg Ser Ala Asn Phe Thr 275 280 285

Asp Asn Ata Lys Thr He He Val Gin Leu Asn Gin Ser Val Glu He 290 295 300

Asn Cys Thr Arg Pro Asn Asn Asn Thr Arg Lys Ser He Arg He Gtn 305 310 315 320

Arg Gly Pro Gly Arg Ala Phe Val Thr He Gly Lys He Gly Asn Met 325 330 335

Arg Gin Ala His Cys Asn He Ser Arg Ala Lys Trp Asn Ala Thr Leu 340 345 350

Lys Gin He Ala Ser Lys Leu Arg Glu Gin Phe Gly Asn Asn Lys Thr 355 360 365

He He Phe Lys Gin Ser Ser Gly Gly Asp Pro Glu He Val Thr His 370 375 380

Ser Phe Asn Cys Gly Gly Gtu Phe Phe Tyr Cys Asn Ser Thr Gtn Leu 385 390 395 400

Phe Asn Ser Thr Trp Phe Asn Ser Thr Trp Ser Thr Glu Gly Ser Asn 405 410 415

Asn Thr Glu Gly Ser Asp Thr He Thr Leu Pro Cys Arg He Lys Gin 420 425 430

Phe He Asn Met Val Gin Glu Val Gly Lys Ala Met Tyr Ala Pro Pro 435 440 445

He Ser Gty Gin He Arg Cys Ser Ser Asn He Thr Gly Leu Leu Leu 450 455 460

Thr Arg Asp Gly Gly Asn Asn Asn Asn Gly Ser Glu He Phe Arg Pro 465 470 475 480

Gly Gly Gly Asp Met Arg Asp Asn Trp Arg Ser Glu Leu Tyr Lys Tyr 485 490 495

Lys Val Val Lys He Glu Pro Leu Gly Val Ala Pro Thr Lys Ala Lys 500 505 510

Arg Arg Val Val Gin Arg Glu Lys 515 520

(2) INFORMATION FOR SEQ ID N0:27:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1532 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 1..1522 (D) OTHER INFORMATION:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

GCA GTC TTC GTT TCG CCC AGC CAG GAA ATC CAT GCC CGA TTC AGA AGA 96 Ala Vat Phe Val Ser Pro Ser Gtn Glu He His Ala Arg Phe Arg Arg 20 25 30

GGC GGC AGA GTA GAA AAG TTG TGG GTC ACA GTC TAT TAT GGG GTA CCT 144 Gly Gly Arg Vat Glu Lys Leu Trp Val Thr Val Tyr Tyr Gty Val Pro 35 40 45

GTG TGG AAA GAA GCA ACC ACC ACT CTA TTT TGT GCA TCA GAT GCT AAA 192 Vat Trp Lys Glu Ala Thr Thr Thr Leu Phe Cys Ala Ser Asp Ala Lys 50 55 60

GCA TAT GAT ACA GAG GTA CAT AAT GTT TGG GCC ACA CAT GCC TGT GTA 240 Ata Tyr Asp Thr Glu Val His Asn Val Trp Ala Thr His Ata Cys Val 65 70 75 80

CCA CTC TGT GTT ACT TTA AAT TGC AAG GAT GTG AAT GCT ACT AAT ACC 432 Pro Leu Cys Vat Thr Leu Asn Cys Lys Asp Val Asn Ala Thr Asn Thr 130 135 140

TCT TTC AAT ATC ACC ACA AGC ATA AGA GAT GAG GTG CAG AAA GAA TAT 528 Ser Phe Asn He Thr Thr Ser He Arg Asp Glu Vat Gin Lys Glu Tyr 165 170 175

GGT TTT GCG ATT CTA AAG TGT AAT GAT AAG ACG TTC AAT GGA AAA GGA 720 Gly Phe Ala He Leu Lys Cys Asn Asp Lys Thr Phe Asn Gly Lys Gly 225 230 235 240 CCA TGT AAA AAT GTC AGC ACA GTA CAA TGT ACA CAT GGA ATT AGG CCA 768 ^Dro Cys Lys Asn Val Ser Thr Val Gtn Cys Thr His Gly He Arg Pro 245 250 255

GTA GTA TCA ACT CAA CTG CTG CTA AAT GGC AGT CTA GCA GAA GAA GAG 816 Vat VaL Ser Thr Gtn Leu Leu Leu Asn Gty Ser Leu Ala Glu Glu Glu 260 265 270

GTA GTA ATT AGA TCT GAC AAT TTC ACG AAC AAT GCT AAA ACC ATA ATA 864 Val t/al He Arg Ser Asp Asn Phe Thr Asn Asn Ala Lys Thr He He 275 280 285

GTA CAG CTG AAA GAA TCT GTA GAA ATT AAT TGT ACA AGA CCC AAC AAC 912 al Gin Leu Lys Glu Ser Val Glu He Asn Cys Thr Arg Pro Asn Asn 290 295 300

ACA GGA GAA ATA ATA GGA GAT ATA AGA CAA GCA CAT TGT AAC ATT AGT 1008 Thr Gly Glu He He Gly Asp He Arg Gin Ata His Cys Asn He Ser 325 330 335

GAA CAA TTT GAG AAT AAA ACA ATA GTC TTT AAT CAC TCC TCA GGA GGG 1104 Gtu Gtn Phe Glu Asn Lys Thr He Val Phe Asn His Ser Ser Gly Gly 355 360 365

GAC CCA GAA ATT GTA ATG CAC AGT TTT AAT TGT GGA GGA GAA TTT TTC 1152 Asp Pro Glu He Val Met His Ser Phe Asn Cys Gty Gly Glu Phe Phe 370 375 380

GAA GGG TCA AAT AAC ACT GAA GGA AAT ACT ATC ACA CTC CCA TGC AGA 1248 Gtu Gly Ser Asn Asn Thr Glu Gly Asn Thr He Thr Leu Pro Cys Arg 405 410 415

ATA AAA CAA ATT ATA AAC ATG GTG CAG GAA GTA GGA AAA GCA ATG TAT 1296 He Lys Gtn He He Asn Met Val Gin Glu Val Gly Lys Ala Met Tyr 420 425 430

AAG GCA AAG AGA AGA GTG GTG CAA AGA GAA AAA T GAGCGGCCGC 1532

Lys Ala Lys Arg Arg Val Val Gin Arg Glu Lys 500 505 (2) INFORMATION FOR SEQ ID N0:28:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 507 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

Met Asp Ala Met Lys Arg Gty Leu Cys Cys Vat Leu Leu Leu Cys Gly 1 5 10 15

Ala Val Phe Val Ser Pro Ser Gin Gtu He His Ata Arg Phe Arg Arg 20 25 30

Gty Gly Arg Val Glu Lys Leu Trp Val Thr Val Tyr Tyr Gty Val Pro 35 40 45

Val Trp Lys Glu Ala Thr Thr Thr Leu Phe Cys Ala Ser Asp Ata Lys 50 55 60

Ata Tyr Asp Thr Glu Val His Asn Vat Trp Ala Thr His Ala Cys Val 65 70 75 80

Pro Thr Asp Pro Asn Pro Gtn Glu Val Vat Leu Gtu Asn Vat Thr Glu 85 90 95

His Phe Asn Met Trp Lys Asn Asn Met Val Glu Gin Met Gin Gtu Asp 100 105 110

He He Ser Leu Trp Asp Gin Ser Leu Lys Pro Cys Vat Lys Leu Thr 115 120 125

Pro Leu Cys Val Thr Leu Asn Cys Lys Asp Val Asn Ala Thr Asn Thr 130 135 140

Thr Asn Asp Ser Glu Gly Thr Met Glu Arg Gly Glu He Lys Asn Cys 145 150 155 160

Ser Phe Asn He Thr Thr Ser He Arg Asp Glu Val Gin Lys Glu Tyr 165 170 175

Ala Leu Phe Tyr Lys Leu Asp Val Val Pro He Asp Asn Asn Asn Thr 180 185 190

Ser Tyr Arg Leu He Ser Cys Asp Thr Ser Vat He Thr Gin Ala Cys 195 200 205

Pro Lys He Ser Phe Glu Pro He Pro He His Tyr Cys Ala Pro Ala 210 215 220

Gty Phe Ala He Leu Lys Cys Asn Asp Lys Thr Phe Asn Gly Lys Gly 225 230 235 240

Pro Cys Lys Asn Val Ser Thr Val Gin Cys Thr His Gly He Arg Pro 245 250 255

Val Val Ser Thr Gin Leu Leu Leu Asn Gly Ser Leu Ala Glu Gtu Glu 260 265 270

Val Val He Arg Ser Asp Asn Phe Thr Asn Asn Ata Lys Thr He He 275 280 285

Vat Gin Leu Lys Glu Ser Val Glu He Asn Cys Thr Arg Pro Asn Asn 290 295 300

Asn Thr Arg Lys Ser He His He Gly Pro Gly Arg Ala Phe Tyr Thr 305 310 315 320

T-ir Gly Glu He He Gly Asp He Arg Gin Ala His Cys Asn He Ser 325 330 335

Arg Ala Lys TΓD Asn Asp Thr Leu Lys Gin He Val He Lys Leu Arg 340 345 350

Glu in Phe Glu Asn Lys Thr He Val he Asn His Ser Ser Gly Gly 355 360 365

Asp Pro Glu He Val Met His Ser Phe Asn Cys Gly Gly Glu Phe Phe 370 375 380

Tyr Cys Asn Ser Thr Gtn Leu Phe Asn Ser Thr Trp Asn Asn Asn Thr 385 390 395 400

Glu Gly Ser Asn Asn Thr Glu Gty Asn Thr He Thr Leu Pro Cys Arg 405 410 415

He Lys Gtn He He Asn Met Val Gtn Glu Val Gty Lys Ata Met Tyr 420 425 430

Ala Pro Pro He Arg Gly Gtn He Arg Cys Ser Ser Asn He Thr Gly 435 440 445

Leu Leu Leu Thr Arg Asp Gly Gly He Asn Glu Asn Gly Thr Gtu He 450 455 460

Phe Arg Pro Gly Gly Gly Asp Met Arg Asp Asn Trp Arg Ser Glu Leu 465 470 475 480

Tyr Lys Tyr Lys Val Val Lys He Glu Pro Leu Gly Val Ala Pro Thr 485 490 495

Lys Ata Lys Arg Arg Val Vat Gin Arg Glu Lys 500 505

(2) INFORMATION FOR SEQ ID NO:29:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 15 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

Ala Pro Thr Lys Ala Lys Arg Arg Val Vat Gin Arg Glu Lys Arg

1 5 10 15

Claims

What is claimed is:

1. A recombinant nucleic acid molecule which encodes a mutant HIV-1 gp120 envelope glycoprotein comprising a V3 loop deletion and a C4 domain_(w-->X) point mutation, wherein X is an amino acid residue other than tryptophan.

2. The recombinant nucleic acid molecule of claim 1, wherein X is a valine residue.

3. The recombinant nucleic acid molecule of claim 1, wherein the nucleic acid molecule is a DNA molecule.

4. The recombinant nucleic acid molecule of claim 3, wherein the DNA molecule is a plasmid.

5. The recombinant nucleic acid molecule of claim 4, wherein the plasmid comprises the sequence of the plasmid designated PPI4-tPA.

6. The recombinant nucleic acid molecule of claim 1, wherein the C4 domain is an HIV-1_LAI gp120 envelope glycoprotein C4 domain.

7. The recombinant nucleic acid molecule of claim 6, wherein the mutant HIV-1 gp120 envelope glycoprotein is a mutant HIV-1_LAI gp120 envelope glycoprotein.

8. The recombinant nucleic acid molecule of claim 1, wherein the C4 domain is an HIV-1_JR-FL gp120 envelope glycoprotein C4 domain.

9. The recombinant nucleic acid molecule of claim 8, wherein the mutant HIV-1 gp120 envelope glycoprotein is a mutant HIV-1_JR-FL gp120 envelope glycoprotein.

10. The mutant HIV-1 gp120 envelope glycoprotein encoded by the recombinant nucleic acid molecule of claim 1.

11. A vaccine which comprises a therapeutically effective amount of the mutant HIV-1 gp120 envelope glycoprotein of claim 10, and an adjuvant.

12. A method of treating an HIV-1-infected subject, which comprises immunizing the HIV-1-infected subject with the vaccine of claim 11, thereby treating the HIV-1- infected subject.

13. A vaccine which comprises a prophylactically effective amount of the mutant HIV-1 gp120 envelope glycoprotein of claim 10, and an adjuvant.

14. A method of reducing the likelihood of an HIV-1-exposed subject's becoming infected with HIV-1, which comprises immunizing the HIV-1-exposed subject with the vaccine of claim 13, thereby reducing the likelihood of the HIV-1-expesed subject's becoming infected with HIV-1.

15. A method of reducing the likelihood of a non-HIV-1- exposed subject's becoming infected with HIV-1, which comprises immunizing the non-HIV-1-exposed subject with the vaccine of claim 13, thereby reducing the likelihood of the non-HIV-1-exposed subject's becoming infected with HIV-1.

16. A method of obtaining partially purified antibodies which specifically bind to the CD4-binding domain of HIV-1 gp120 envelope glycoprotein, which method comprises (a) immunizing a non-HIV-1-exposed subject with the vaccine of claim 13, (b) recovering from the immunized subject serum comprising said antibodies, and (c) partially purifying said antibodies, thereby obtaining partially purified antibodies which specifically bind to the CD4-binding domain of HIV-1 gp120 envelope glycoprotein.

17. The method of claim 16, wherein the subject is a human.

18. The partially purified antibodies produced by the method of claim 16.

19. A pharmaceutical composition, which comprises a therapeutically effective amount of the partially purified antibodies of claim 18, and a pharmaceutically acceptable carrier.

20. A method of treating an HIV-1-infected subject, which comprises administering to the subject a dose of the pharmaceutical composition of claim 19 effective to reduce the population of HIV-1-infected cells in the HIV-1-infected subject, thereby treating the HIV-1- infected subject.

21. A method of treating an HIV-1-infected subject, which comprises administering to the subject a dose of the pharmaceutical composition of claim 19 effective to reduce the population of HIV-1 in the HIV-1-infected subject, thereby treating the HIV-1-infected subject.

22. A composition which comprises a prophylactically effective amount of the partially purified antibodies of claim 18, and a pharmaceutically acceptable carrier.

23. A method of reducing the likelihood of an HIV-1-exposed subject's becoming infected with HIV-1, which comprises administering to the HIV-1-exposed subject a dose of the composition of claim 22 effective to reduce -the population of HIV-1 in the HIV-1-exposed subject, thereby reducing the likelihood of the subject's becoming infected with HIV-1.

24. The method of claim 23, wherein the subject is a medical practitioner.

25. The method of claim 23, wherein the subject is a newborn infant.

26. A method of reducing the likelihood of a non-HIV-1- exposed subject's becoming infected with HIV-1 as a result of exposure thereto during an incident wherein there is an increased risk of exposure to HIV-1, which comprises administering to the subject immediately prior to the incident a dose of the composition of claim 22 effective to reduce the population of HIV-1 to which the subject is exposed during the incident, thereby reducing the likelihood of the subject's becoming infected with HIV-1.

27. The method of claim 26, wherein the subject is a medical practitioner.